Green nanotechnology of MGF‑AuNPs for immunomodulatory intervention in prostate cancer therapy by Khoobchandani, Menka et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2021 
Green nanotechnology of MGF‑AuNPs for immunomodulatory 
intervention in prostate cancer therapy 
Menka Khoobchandani 
Aslam Khan 
Kavita K. Katti 
Velaphi C. Thipe 
Amal Y. Al-Yasiri 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Menka Khoobchandani, Aslam Khan, Kavita K. Katti, Velaphi C. Thipe, Amal Y. Al-Yasiri, Darsha K. D. 
MohanDoss, Michael B. Nicholl, Ademar B. Lugão, Chetan P. Hans, and Kattesh V. Katti 
1
Vol.:(0123456789)





intervention in prostate cancer 
therapy
Menka Khoobchandani1,2, Aslam Khan3, Kavita K. Katti1, Velaphi C. Thipe4, 
Amal Y. Al‑Yasiri5,6, Darsha K. D. MohanDoss7, Michael B. Nicholl8, Ademar B. Lugão4, 
Chetan P. Hans9 & Kattesh V. Katti1,10,11*
Men with castration‑resistant prostate cancer (CRPC) face poor prognosis and increased 
risk of treatment‑incurred adverse effects resulting in one of the highest mortalities among 
patient population globally. Immune cells act as double‑edged sword depending on the tumor 
microenvironment, which leads to increased infiltration of pro‑tumor (M2) macrophages. 
Development of new immunomodulatory therapeutic agents capable of targeting the tumor 
microenvironment, and hence orchestrating the transformation of pro‑tumor M2 macrophages to 
anti‑tumor M1, would substantially improve treatment outcomes of CRPC patients. We report, herein, 
Mangiferin functionalized gold nanoparticulate agent (MGF‑AuNPs) and its immunomodulatory 
characteristics in treating prostate cancer. We provide evidence of immunomodulatory intervention of 
MGF‑AuNPs in prostate cancers through observations of enhanced levels of anti‑tumor cytokines (IL‑
12 and TNF‑α) with concomitant reductions in the levels of pro‑tumor cytokines (IL‑10 and IL‑6). In the 
MGF‑AuNPs treated groups, IL‑12 was elevated to ten‑fold while TNF‑α was elevated to about 50‑fold, 
while IL‑10 and IL‑6 were reduced by two‑fold. Ability of MGF‑AuNPs to target splenic macrophages 
is invoked via targeting of NF‑kB signaling pathway. Finally, therapeutic efficacy of MGF‑AuNPs, in 
treating prostate cancer in vivo in tumor bearing mice, is described taking into consideration various 
immunomodulatory interventions triggered by this green nanotechnology‑based nanomedicine 
agent.
Abbreviations
ABLR  Laminin receptor antibody
ARRIVE  Animal Research: Reporting of In Vivo Experiments
BSA  Bovine serum albumin
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CBC  Complete blood count
CPZ  Chlorpromazine
CRPC  Castration-resistant prostate cancer
CFSE  Carboxyfluorescien succinimidyl ester
DAPI  4′,6-Diamidino-2-phenylindole
DCFH-DA  2,7-Dichlorofluorescin diacetate
DPBS  Dulbecco’s phosphate buffered saline
DLS  Dynamic Light Scattering
DU-145  Androgen receptor positive human prostate cancer cells
EDS  Energy-dispersive X-ray spectroscopy
EGCG  Epigallocatechin gallate
EGFR  Epidermal growth factor
EMT  Epithelial-mesenchymal transition
FACS  Fluorescence-Activated Cell Sorting
FGFR  Fibroblast growth factor
Fn-3  Anti-fibronectin AB
FITC  Fluorescein isothiocyanate
HSA  Human serum albumin
HAECs  Human aortic endothelial cells
IAEA  United Nation’s International Atomic Energy Agency
ICP-MS  Inductively Coupled Plasma Mass Spectrometry
IKK  IκB kinase
IκBs  NF-κB proteins
LNCaP  Lymph node carcinoma of the prostate cell line
M1  Anti-tumor macrophages
M2  Pro-tumor macrophages
MDSCs  Myeloid-derived suppressor cells
MGF  Mangiferin
MGF-AuNPs  Mangiferin functionalized gold nanoparticles
MMP  Matrix metalloproteinase
MLuC5  Laminin receptor antibody
MPS  Mononuclear phagocyte system
MVD  Micro-vessel density
MURR  University of Missouri Research reactor
NAA  Neutron Activation Analysis
NF-kB  Nuclear factor kappa-light-chain-enhancer of activated B cells
NK  Natural killer
LPS  Lipopolysaccharide
PBS  Phosphate buffered saline
PC-3  Human prostate tumor cells
PCR  Polymerase chain reaction
PDGFR  Platelet derived growth factor
PFA  Paraformaldehyde
PI  Propidium iodide
PXRD  Powder X ray diffraction
RAW 264.7  Murine macrophage cells
RPMI  Roswell Park Memorial Institute
S-AuNPs  Starch-stabilized gold nanoparticles
SCID  Severely combine immune-deficient
SCNC  Small Cell Neuroendocrine Carcinoma
SPR  Surface plasmon resonance
TAMs  Tumor associated macrophages
TEM  Transmission Electron Microscopy
TNF-α  Tumor necrosis factor alpha
VEGFR  Vascular endothelial growth factor
X-22  Anti-clathrin AB
The latest epidemiological investigation (spanning January 1, 2008–March 31, 2018) of patients with castration-
resistant prostate cancer (mCRPC) has concluded high mortality suggesting a significant unmet clinical need 
in prolonging life span of human population inflicted with this deadly disease  globally1–4. There is an emerg-
ing consensus that current therapies are poorly effective for patients with castration-resistant prostate cancer 
(CRPC), where the disease manifests from asymptomatic or minimally symptomatic, non-metastatic disease to 
symptomatic or highly metastatic condition, depending on the time of diagnosis with significant interpatient 
 variation5–7. The United States Food and Drug Administration (FDA) has approved several chemotherapeutic 
agents including docetaxel, cabazitaxel, abiraterone, and enzalutamide for treating such patients. Drug resistance, 
attributable to modulation of myeloid-derived suppressor cells (MDSCs), is seen in a significant proportion of 
CRPC patients. Myeloid-derived suppressor cells (MDSCs) induce an immune suppressive microenvironment 
and promote the M2-polarized tumor associated macrophages (TAMs). These macrophages present remarkable 
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ability to suppress T-cell responses thus supporting angiogenesis and metastasis of CRPC. Macrophages, the 
myeloid derived immune cells of the innate immune system, manifest two states of polarization (M1 and M2) 
that develop in direct response to different stimuli. The polarization and differentiation of macrophages into 
the cancer-inhibiting M1 and cancer-promoting M2 phenotypes represent the two states of macrophages in the 
tumor  microenvironment8–10.
Numerous studies have also shown that tissue and serum exosomes from prostate cancer patients induced 
higher levels of macrophage polarization into an alternatively activated M2 (pro-tumor)  phenotype11–13. The 
interaction of polarized macrophages with cancer cells plays a crucial role in a variety of cancers including 
prostate  cancers9,14,15. Several investigations have provided important insights on the role of the polarization of 
macrophages from M1 into M2 phenotypes and how this macrophage axis is directly involved in prostate cancer 
initiation, progression, and  metastasis16–18. An additional contributing factor for enhanced levels of pro-tumor 
M2 phenotypes in a vast majority of prostate and most solid tumors is attributed to elevated NF-κB signaling, 
upregulated by the release of cytokines by M2 macrophages, in the tumor  microenvironment19,20. Compelling 
evidence shows that chemotherapeutic and radiation treatments of solid cancers in general, and prostate tumors 
in particular, activates NF-κB, a key transcription factor that plays a critical role in the development and progres-
sion of cancers and consequently aiding chemo and multi therapy drug resistance. Upregulated NF-κB activity 
can activate pro-survival pathways, including BCL-2. Therefore, cancer treatment emphasizing personalized 
therapy through immune boosting precision medicine, capable of targeting M2 macrophages, is distinguished 
from a plethora of “common denominator” treatment approaches in current  use21–23.
In the context of developing novel therapies for treating drug-resistant cancers such as castration-resistant 
prostate cancer (CRPC), high antioxidant capacity and immunomodulatory phytochemicals are gaining consider-
able scientific and clinical  interests24,25. Anti-neoplastic activity of phytochemicals mainly depends on their multi-
target mechanism of action, including their ability to modulate the host immune response to cancer, reducing 
inflammatory microenvironment and enhancing lymphocyte  oncosurveillance26–28. Numerous therapeutic effects 
of various phytochemicals are believed to be based on mechanisms of modulation of innate immunity more 
specifically macrophage  function29,30. Since carcinogenesis is multi-factorial activity involving several signaling 
pathways, multi targeted phytochemicals therefore represent a promising therapeutic domain in  oncology31,32. 
However, one of the major challenges, which continue to impede the application of phytochemicals, in cancer 
treatment is associated with achieving adequate bioavailability at tolerable doses. This is a vexing problem in 
translating promising findings from cell culture and animal models into clinically efficacious phytochemical-
based drugs.
Nanotechnology offers practical and scientifically most effective means to create multitudes of signatures of 
phytochemicals on individual nanoparticles—thus enhancing bioavailability to achieve optimum therapeutic 
payloads at the tumor  site33–35. Over the last two decades, we have successfully demonstrated that large surface 
area of gold nanoparticles can be embedded with a plethora of phytochemicals to create biocompatible cancer 
therapeutic nanomedicine  agents33–51. Our extensive results, using tumor bearing rodents as well as in tumor 
bearing dogs (where the disease mimics spontaneously occurring tumors in human patients), have demonstrated 
optimum therapeutic efficacy using tolerable  doses33–51. Our investigations, therefore, provide compelling ration-
ale to develop phytochemical-embedded immunomodulatory nanomedicine agents for use in a wide array of 
applications in  oncology33–51.
In view of the extraordinary importance of immunomodulatory intervention in treating mCRPC, we focused 
our attention on the creation of Mangiferin encapsulated gold nanoparticles (MGF-AuNPs). Mangiferin, used 
extensively in ancient medicine, is a glucose-functionalized xanthonoid found in large abundance in mangoes 
fruit  peel52. Several studies have shown that Mangiferin exerts antioxidant activities, inhibitory effects on type II 
5α-reductase in vitro, gastroprotective and also antidiabetic effects in  rodents53–57. Administration of Mangiferin 
in swiss mice have shown in vivo growth-inhibitory activity against ascitic  fibrosarcoma58. This phytochemical 
has demonstrated enhanced tumor cell cytotoxicity of the splenic cells and peritoneal macrophages of normal 
and tumor-bearing  mice59. Mechanistic investigations have revealed that Mangiferin causes decreased matrix 
metalloproteinase (MMP)-7 and -9 activities with concomitant reversal of epithelial-mesenchymal transition 
(EMT)60. There is conclusive evidence that the mechanism of modulation of MMP-7 and -9, and EMT is due to 
the innate ability of Mangiferin to inhibit β-catenin  pathway61,62. Enzymatic degradation, in vivo, has impeded 
the clinical applications of this important immunomodulatory phytochemical in oncology.
Our hypothesis was that encapsulation of Mangiferin (MGF) on gold nanoparticles would create a new 
nanomedicine agent, MGF-AuNP, enabling improved cellular uptake of MGF-AuNPs for exerting effective 
immunomodulatory intervention via targeting the tumor microenvironment. In the present article, we give a 
conceptual overview on how a new generation of immunotherapeutic agent derived through green nanotechnol-
ogy, integrating Mangiferin phytochemical onto well-defined gold nanoparticles (MGF-AuNPs), can be devel-
oped for use in prostate cancer therapy. Interestingly, combination of gold metal with phytochemicals has been 
used for over 5000 years in the Indian holistic Ayurvedic  Medicine63–71. Our green nanotechnology approach 
of encapsulating Mangiferin onto gold nanoparticles represents an integrative momentum to merge the best of 
two worlds of modern nanomedicine with the traditional Ayurvedic medicine.
We describe, herein, experimental evidence that Mangiferin functionalized gold nanoparticulate nano-
medicine agent, (MGF-AuNPs), successfully manipulates the M1 and M2 polarization axis through two main 
approaches for applications in prostate cancer therapy: (1) specific interference with M2-like tumor associated 
macrophages (TAM) survival or inhibiting their signaling cascades and (2) repolarization of tumor-promoting 
M2-like TAMs to a tumoricidal M1-like phenotype. We also describe evidence of immunomodulatory inter-
vention of MGF-AuNPs in prostate cancers through observations of enhanced levels of anti-tumor cytokines, 
such as IL-12 and TNF-α, with concomitant reductions in the levels of pro-tumor cytokines, such as IL-10 and 
IL-6. Additionally, we provide concrete details on cellular interrogation to establish that MGF-AuNPs target 
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laminin receptors, over expressed on prostate tumor cells, thus presenting a compelling case for applications 
of this nanomedicine agent in the treatment of laminin receptor-positive human tumors for both diagnosis 
and therapy. Ability of MGF-AuNPs to target splenic macrophages is invoked via targeting of NF-κB signaling 
pathway; and thus, resulting in reeducation/polarization of macrophages from pro-tumor M2 to anti-tumor M1 
macrophages. Finally, therapeutic efficacy of MGF-AuNPs, in treating prostate cancer in vivo in tumor bearing 
mice, is described taking into consideration various immunomodulatory interventions triggered by this green 
nanotechnology-based nanomedicine agent. Full mechanistic details of immunotherapeutic effects of MGF-
AuNPs and how tumor microenvironment targeting ability of this nanomedicine agent will play a crucial role 
in prostate tumor therapy are described.
Results and discussion
Green nanotechnological architecture of MGF‑AuNPs. Mangiferin (1,3,6,7-tetrahydroxyxanthone-
C2-D glucoside) is a polyphenol comprising of D-glucoside functionalized with a xanthone (Scheme 1)72. This 
phytochemical is found in abundance in the Anacardiaceae and Gentianaceae family of plant species especially 
in mango skin and honeybush  tea73. Following our pioneering efforts of using Phytochemicals of plants to pro-
duce tumor specific gold  nanoparticles33–51, we have utilized a highly innovative green nanotechnology process 
to functionalize Mangiferin onto gold nanoparticles to produce Mangiferin encapsulated gold nanoparticles: 
MGF-AuNPs (Scheme 1). Antioxidant phytochemicals can act as electron reservoirs to transform metals into 
their corresponding nanoparticles. The high antioxidant capacity of Mangiferin, as reflected through its oxida-
tion potential (Epa = 0.32 V), offered a unique opportunity to use this phytochemical to transform gold salt into 
the corresponding nanoparticles (AuNPs). We have now optimized a highly reproducible and a scalable process 
wherein interaction of appropriate amounts of Mangiferin with gold salt produced the corresponding phyto-
chemical-encapsulated gold nanoparticles (MGF-AuNPs) in aqueous media (Scheme 1). The excess Mangiferin 
from the reaction mixture creates a robust encapsulation around gold nanoparticles thus eliminating the need 
for external chemical agents for stabilization against agglomeration of MGF-AuNPs. The green nanotechnology 
process, as depicted in Scheme 1, offers a great example of a ‘zero carbon footprint’ process because, other than 
the gold salt, no other human-derived toxic chemicals were used in the overall production of MGF-AuNPs. 
Full characterization details of MGF-AuNPs using combinations of techniques including UV–visible Spectro-
photometry, Dynamic Light Scattering (DLS), Transmission Electron Microscopy (TEM), Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS), Energy-Dispersive X-ray Spectroscopy (EDS) and Powder X ray Diffrac-
tion (PXRD)—are all outlined in the supplementary materials section (Figures S1–S4).
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Prostate tumor cell specificity and receptor mediated endocytosis of MGF‑AuNPs. We ration-
alized the choice PC-3 cells in our investigations based on ample evidence that suggests that PC-3 and DU-145 
are androgen receptor deficient cells and that they do not respond to hormone therapy. One of the ways of treat-
ing patients with androgen receptor deficient conditions is through castration. However, this strategy does not 
improve the survival outcome significantly. Between PC-3 and DU-145, PC-3 tumors are more aggressive and 
metastatic. Androgen therapy resistant prostate tumors are more aggressive, metastatic, and fatal. Consider-
ing all these facts, we chose PC-3 cell line to develop xenograft tumors in severely combine immune-deficient 
(SCID) mice (see subsequent sections on therapeutic efficacy to address treatment inefficiency of current treat-
ment strategies for androgen (castration)-resistant prostate cancers). We did not use androgen therapy sensitive 
prostate cancer cell line as we focused our efforts on CRPCs.
Previous studies from our laboratories have shown that polyphenolic structural motif of epigallocatechin 
gallate (EGCG) exhibit selective binding affinities (in the sub nanomolar ranges) with laminin receptors which 
are overexpressed in prostate and various other tumor  cells33,41. We reasoned that the chemical structure of 
Mangiferin, which comprises of a glucose moiety (Scheme 1), should allow significantly efficient accumulation 
of MGF-AuNPs within tumor cells due to the Warburg  effect74,75. We hypothesized that the Warburg effects, 
in conjunction with laminin receptor specificity of Mangiferin, are expected to provide selective and enhanced 
tumor accumulation of MGF-AuNPs in tumor cells. In order to establish laminin receptor specificity and high 
binding affinity of MGF-AuNPs toward laminin receptors, we have performed detailed mechanistic investigations 
on the endocytosis pathways of MGF-AuNPs in prostate tumor cells as discussed below.
It is well-known that prostate tumor cells overexpress laminin receptors (67 kDa LR)76. Laminin receptor is an 
important protein involved in cell adhesion to the basement membrane as well as in the signaling transduction 
following this binding  event77. In our experiments, we have probed the specificity of MGF-AuNPs toward laminin 
receptors that are over expressed in prostate tumor cells derived from human prostate tumors (PC-3 cells) (Fig. 1, 
Scheme 2). Briefly, PC-3 cells were treated with MGF-AuNPs, in two separate experiments involving the pres-
ence and absence of laminin receptor antibody  (MLuC5), in our efforts to discern the laminin receptor mediated 
endocytosis of MGF-AuNPs. When the laminin receptors were not blocked by  MLuC5 antibody, we observed very 
efficient endocytosis of MGF-AuNPs into PC-3 cells as shown in Fig. 1B (Dark field microscopy) and E (Trans-
mission electron microscopy). We then saturated the laminin receptors on PC-3 cells using  MLuC5 antibody 
and subsequently allowed these cells to interact with MGF-AuNPs. Microscopic analysis of these cells clearly 
revealed inhibition of MGF-AuNPs to internalize into PC-3 cells as shown in Fig. 1C (Dark field microscopy) 
Figure 1.  Receptor mediated endocytosis of MGF-AuNPs. (A,D): Untreated PC-3 cells; (B,E): MGF-AuNPs 
(41 µM) treated PC-3 cells; (C,F): Laminin receptors on PC-3 cells blocked with ABLR antibody and post 
treated with MGF-AuNPs, results from images B and E showing laminin receptor affinity of MGF-AuNPs in 
PC-3 cells. Optical images by dark field microscopy (CytoViva) and microscopic images by TEM techniques.
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and F (Transmission electron microscopy). We rationalize our findings on the basis that pre-incubation of PC-3 
cells with  MLuC5 antibody saturates Lam 67 receptors on prostate cancer cells and thus reduces or eliminates the 
ability of MGF-AuNPs to bind to laminin receptors on these cells. The above results, of pre- and post-blocking, 
of laminin receptors by  MLuC5 antibody—taken together—unequivocally reveal that Mangiferin corona, on 
MGF-AuNPs, serves as a powerful laminin receptor targeting agent. These results, therefore, provide compelling 
evidence that MGF-AuNPs have the potential for use as tumor specific gold nanoparticles in molecular imaging 
and therapy of various laminin receptor-positive tumors.
In order to further establish tumor cell specificity of MGF-AuNPs, we have performed laminin receptor block-
ing experiments using a non-specific antibody, anti-fibronectin AB (Fn-3), and mouse IgG Isotype as a control. 
Our selection of these antibodies in blocking experiments is based on prior evidence that they do not have known 
specificity towards laminin receptors on PC-3 cells. In these experiments, PC-3 cells were pre-treated with both 
the antibodies separately followed by treatment with MGF-AuNPs for 60 min. Post incubation, the dark field 
microscopic and TEM analysis of tumor cells indicated that these antibodies failed to block the endocytosis of 
MGF-AuNPs within PC-3 cells (Fig. 2E,F,I,J). In fact, the high propensity of endocytosis of MGF-AuNPs into 
PC-3 cells, post incubation with anti-fibronectin AB (Fn-3), and mouse IgG Isotype, was very similar to the 
results we have observed with the unblocked PC-3 cells (Fig. 2A). These detailed cellular interrogation investiga-
tions, as described above, clearly establish that MGF-AuNPs target laminin receptors on prostate tumor cells and 
thus reinforce their prospects for applications in the treatment of prostate and related tumors.
Clathrin vs caveolae‑mediated endocytosis and cell trafficking pathways of MGF‑AuNPs. In 
order to understand the precise nature of the interaction MGF-AuNPs with prostate cellular (PC-3) membrane, 
we have explored further on the mode of endocytosis using two independent techniques involving dark field 
microscopy and transmission electron microscopy (TEM). The internalization and uptake of MGF-AuNPs with 
PC-3 cells were studied by incubating nanoparticles at various dilutions at select time points. Microscopic analy-
sis of tumor cells, post incubation periods, revealed that MGF-AuNPs bind to prostate cell membrane within 
30 min and internalize into the cells within 60 min of incubation time (Fig. 3A–F). Once the nanoparticles are 
accumulated on the cell membrane, these tumor cells appear to form a cavity like structure on the cell membrane 
to engulf the AuNPs (Fig. 3C). These detailed time dependent studies suggested that MGF-AuNPs internalize 
into the tumor cells presumably through clathrin/caveolae mediated endocytosis. Generally, clathrin and cave-
olae mediated endocytosis follow receptor-mediated tumor-specific pathway whereas phagocytosis or pinocy-
tosis follow non-specific pathways. In order to confirm that MGF-AuNPs are internalized through clathrin and/
or caveolae mediated tumor specific endocytosis, and not through the non-specific phagocytosis or pinocytosis 
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pathways, we performed additional experiments involving pre-blocking clathrin coated pit using ‘chlorprompa-
zine (CPZ)’ reagent followed by incubation with MGF-AuNPs. Microscopic examinations of tumor cells from 
these clathrin blocking experiments revealed that significantly lower quantitates of MGF-AuNPs are internal-
ized into tumor cells as shown in Fig. 2B,C,G. These results clearly suggested that the mechanism of cell sur-
face receptor uptake, and subsequent internalization of MGF-AuNPs, is mediated through clathrins. This is an 
important observation because clathrin mediated endocytosis are primarily responsible for subsequent intracel-
lular downstream signaling and modulation of endocytic trafficking (discussed in subsequent sections)78,79. Our 
observations of clathrin-mediated endocytosis of MGF-AuNPs is of vital significance in prostate tumor therapy 
because recent investigations have shown that clathrin-mediated internalization of Cadherin-11 (Cad11) regu-
lates surface trafficking of Cad11. It is well-known that Cadherin-11 cell adhesion molecule plays an important 
role in prostate cancer cell migration and that migratory function of Cad11 in prostate cancer cells is regulated 
through dynamic turnover of  Cad1179.
We further focused our attention to test if MGF-AuNPs are also following caveolae-mediated pathway for 
internalization within prostate tumor cells. Several pre-clinical and clinical investigations have suggested that 
expression of Caveolin-1 (Cav-1), an integral membrane protein expressed in two isoforms (Cav-1α and Cav-1β), 
as a significant prognostic marker for prostate  cancer80. Cav-1 is overexpressed in prostate cancer cells and is 
associated with the progression, cell survival and angiogenic activities of the  disease81. Therefore, we reasoned 
to explore if the efficient endocytosis of MGF-AuNPs, as depicted in Fig. 2D,H, is mediated through caveolae 
pathway. Towards this objective, we performed experiments to first block caveolae on prostate tumor cells by 
incubating them with Anti-Caveolin-1 antibody. Post blocking of caveolae on prostate tumor cells, we incubated 
these cells with MGF-AuNPs and subsequently performed detailed microscopic analysis. Dark field microscopic 
images of PC-3 cells with and without caveolae blocking, as shown in Fig. 2D,H, suggested little/no difference, 
between the pre and post caveolae blocking, in the amounts of nanoparticles that were internalized. These find-
ings, therefore, revealed that the mechanism of endocytosis of MGF-AuNPs in PC-3 cells is not mediated through 
caveolae expression and indeed occurs primarily through clathrin mediation as described above.
Tumor targeting capabilities of MGF-AuNPs, as shown through extensive prostate tumor cell trafficking 
assays outlined above, prompted us to test the potential toxicity of these nanoparticles toward normal cells. The 
results are summarized in the following sections.
Figure 2.  Clathrin mediated endocytosis of MGF-AuNPs (A–F): Dark field (CytoViva) microscopic images; 
(G–J): TEM Images showing PC-3 cells pretreated with Chlorpromazine, anticlarthrin AB, anti-caveolae AB, 
anti-fibronectin AB, and mouse IgG Isotype control AB, followed by treatment with MGF-AuNPs (41 µM). 
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Interaction of MGF‑AuNPs with normal cells. In order to elucidate that MGF-AuNPs are tumor cell 
specific and that they have minimal or no affinity toward normal cells, we have further evaluated cellular interac-
tion of MGF-AuNPs using human aortic endothelial cells (HAECs). We hypothesized that MGF-AuNPs selec-
tively target prostate tumor cells due to their overexpression of laminin receptors and that they cause minimal/
no toxicity to normal cells because normal cells exhibit minimum laminin receptor  density82. Therefore, we 
incubated MGF-AuNPs with endothelial cells (HAECs) and looked for the uptake of gold nanoparticles in these 
cells through electron microscopy. The results presented in Fig. 4A,B, confirmed that HAECs showed minimum 
uptake of MGF-AuNPs at the same dose and time point (41 µM; 60 min incubation) as was used for similar 
experiments with prostate tumor cells (PC-3). These results are of profound importance in the context of vari-
ous applications of MGF-AuNPs as a tumor specific therapeutic agent with minimal/no toxicity to normal cells.
These detailed cellular interrogation investigations, as described above, have clearly established that MGF-
AuNPs target laminin receptors on prostate tumor cells and that they exhibit minimal/no toxicity to normal 
cells. Exploring the effects of MGF-AuNPs on prostate tumor and normal HAECs cell viability was the next 
logical step in our quest to validate the applicability of MGF-AuNPs as a tumor specific nanomedicine agent.
Effects of MGF‑AuNPs on prostate tumor and normal HAECs cell viability. We have performed 
MTT assays to evaluate viability of prostate tumor and HAECs cells upon treatment with MGF-AuNPs. Choice 
of PC-3 cells was rationalized based on their innate metastatic nature. Serial dilutions of MGF-AuNPs were pre-
pared in RPMI media to treat with PC-3 cells. The cell viability profiles, as shown in Fig. 5A, inferred that these 
nanoparticles exhibited dose dependent efficacy for causing death of cancer cells. Figure 5A depicts increased 
reduction in cancer cell viability with increasing concentrations of the MGF-AuNPs agent over a period of 48 
and 72 h. At each of the concentrations, we observed reduced cell viability as compared to the control untreated, 
and a significant reduction of tumor cells was noted at a concentration of 165 µM and beyond. Starch stabilized 
gold nanoparticles (S-AuNPs) as well as Gum-Arabic stabilized gold nanoparticles (GA-AuNPs) were used as 
control NPs group for the in vitro experiments in all the cell viability assays to demonstrate minimal/no effect of 
control group of nanoparticles on cells (For details, see supplementary materials section; Figure S5).
In summary, MTT cell viability assay for prostate tumor cells and normal cells (Fig. 5A,B), taken together, with 
results from control group of gold nanoparticles (Figure See supplementary materials section; Figure S5), demon-
strated that MGF-AuNPs presented dose limiting selective toxicity to tumor cells with no effect on normal cells.
Evaluation of induction of apoptotic vs necrotic cancer cell death patterns of MGF‑AuNPs on 
PC‑3 cells. We wanted to test if the mechanism of tumor cell death, when MGF-AuNPs interacted with 
Figure 3.  Time dependent internalization of MGF-AuNPs (41 µM) into PC-3 cells, images observed by TEM. 
(A) At 30 min; (B,C) at 60 min; (D,E) at 90 min; (F) at 120 min.
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Figure 4.  TEM images showing minimal uptake of MGF-AuNPs into human aortic endothelial cells (HAECs), 
60 min post treatment of MGF-AuNPs (41 µM). (A) HAECs cells control; no treatment; (B) MGF-AuNPs 
treated cells (41 µM).
Figure 5.  MGF-AuNPs inhibit the proliferation of PC-3 cells and not HAECs. (A) PC-3 cells were cultured in 
96 well plates overnight for adherence and rest. The cells were treated with indicated doses of MGF-AuNPs and 
for 48 and 72 h. MTT assay was performed at the end of the treatment. (B) HAECs were cultured overnight in 
96 well plates for rest and adherence. The cells were treated MGF-AuNPs for indicated times and doses. MTT 
assay was performed at the end of the treatment.
10
Vol:.(1234567890)
Scientific Reports |        (2021) 11:16797  | https://doi.org/10.1038/s41598-021-96224-8
www.nature.com/scientificreports/
PC-3 cells, is driven through a regulated programmed cell death (apoptosis), or through a passive, uncontrolled 
necrosis course. Apoptotic cells are measured by their cell membrane disruption, chromatic condensation, and 
DNA degradation which leads to cell death. In our assays, we used flow cytometry and fluorescent microscopic 
techniques to visualize patterns of early and late apoptosis by PI and FITC-Annx V staining. Cells with early 
apoptosis are FITC (+ ve) and PI (− ve), whereas cells at late apoptotic stages are FITC (+ ve) and PI (+ ve). Our 
results have confirmed that PC-3 cells treated with MGF-AuNPs showed 40% total cell death including early and 
late-stage apoptosis at a dose of 83 µM compared to untreated controls (14.38%) (Fig. 6A) which is 278% more 
than the control cells. These results provide important insights that MGF-AuNPs exert apoptotic influence on 
PC-3 cells in tumor selective therapy. We have further verified, the Annexin V/PI assay results, through care-
ful observations of cellular morphology of PC-3 cells upon treatment with MGF-AuNPs. The results presented 
in Fig.  6B indicated that cells treated with MGF-AuNPs exhibited significantly more apoptosis compared to 
untreated control cells. Early apoptotic cells are colored in green whereas late stage apoptotic and/or necrotic 
cells are colored in red (Fig. 6B). It may be discerned, from Fig. 6A,B that more cells were found in early and 
late apoptotic stages, in the MGF-AuNPs treatment group, as compared to the untreated control group. It is also 
significant to recognize that MGF-AuNPs, at the dose of 83 µM, showed almost similar pattern of apoptotic cells 
death as was observed upon treatment of cancer cells with the standard drug ‘Staurosporine’ (Fig. 6B). In sum-
mary, all our results, taken together, unequivocally, confirmed that MGF conjugated-AuNPs induced apoptosis 
of cancer cells through early-stage apoptotic phase, and finally resulting in effective programmed cancer cell 
death.
Anti‑angiogenesis activity of MGF‑AuNPs. Angiogenesis plays a vital role in the overall growth pro-
cess of cancers as it dictates the migration and differentiation of endothelial cells, which line the inside wall of 
blood  vessels83. Chemical signals in the body control the rapidity of angiogenesis by providing efficient blood 
supply that stimulate angiogenesis as well as stimulate nearby normal cells to produce angiogenesis signaling 
 molecules84. The ligand-receptor pairs such as vascular endothelial growth factor (VEGF)-VEGFR (receptor), 
platelet derived growth factor (PDGF)-PDGFR, fibroblast growth factor (FGF)-FGFR, and epidermal growth 
Figure 6.  MGF-AuNPs produced apoptosis in PC-3 cells and inhibits endothelial cell tube formation: (A,B) 
PC-3 cells were cultured in 6 well plates for overnight followed by treatment with MGF-AuNPs for 24 h. The 
cells were harvested and permeabilized. After permeabilization the cells were stained with Annexin V for 
membrane damage and with Propidium Iodide (PI) for DNA damage. The cells were washed and analyzed by 
either flow cytometry or fluorescent microscopy; (C) 6 well plates were layered with Matrigel and HAECs were 
cultured on the Matrigel for tube formation. AuNPs at 41 and 83 µM for 24 h were added to the culture. Tube 
formation was observed under the light microscope and pictures were taken.
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factor EGF-EGFR affect the  angiogenesis85. Therefore, angiogenesis inhibiting agents are pivotal in the effective 
treatment of various cancers, particularly the solid tumors. We have, therefore, performed additional studies to 
elucidate the anti-angiogenesis capabilities of MGF-AuNPs through capillary tube structures formation assay. 
Phase contrast microscopic images, as depicted in Fig. 6C, clearly showed that the HAECs cells, pre-incubated 
with MGF-AuNPs nanomedicine agent, at 41 and 83 µM doses effectively inhibited the formation of capillaries 
as compared to the control untreated group, where the complete vasculature structure was seen intact (Fig. 6C). 
Angiogenesis plays a critical role in the growth of cancers because solid tumors need blood supply if they are to 
grow beyond a few millimeters in  size83. Tumors can actually cause this blood supply to form by giving off chem-
ical signals that stimulate angiogenesis. Tumors can also stimulate nearby normal cells to produce angiogenesis 
signaling  molecules84. Vinblastine has emerged as an effective microtubule destabilizing agent because of its 
ability to target tubulin, thus inhibiting its polymerization and the subsequent association of microtubules. The 
superior antiangiogenic features of vinblastine restrain the tumor growth while decelerating malignant angio-
genesis in a vast majority of human  cancers86,87. Therefore, we have compared the antiangiogenic characteristics 
of MGF-AuNPs with the FDA approved vinblastine. Our results, as depicted in Fig. 6C, compellingly infer that 
the anti-angiogenesis effects of MGF-AuNPs are comparable with the FDA approved drug vinblastine. These 
findings provide compelling evidence on the vast potential of MGF-AuNPs for use as an anti-angiogenesis agent 
in oncology.
Role of nuclear factor kappa B (NF‑κB) transcription factor in prostate cancer. In the context 
of prostate cancer, several clinical investigations, involving human prostate cancer patients, have shown strong 
correlations between increased frequency of NF-κB p65 and a risk of disease  progression88. Indeed, the identi-
fication of patients with high-risk prostate cancer (PC) and its direct association with the nuclear localization 
of NF-κB p65, from cohorts of patients, has generated considerable interest in the tremendous prognostic clini-
cal value of this cell signaling pathway as a potential prognostic parameter in gauging treatment outcomes of 
advanced stage prostate cancer  patients89. Therefore, we have probed the potential utility of MGF-AuNPs as a 
NF-κB targeting agent through interactions with PC-3 prostate tumor cells from the human prostate tumor 
origin.
MGF‑AuNPs target nuclear factor kappa B (NF‑κB) transcription factor. Nuclear factor kappa B 
(NF-κB) constitute a family of genes acting in concert in malignant tumor invasion, migration and metastasis, 
of various human cancers including breast, colon, lung, oral, pancreatic, and prostate  cancers90,91. Several inves-
tigations have inferred that (NF-κB) activation is directly responsible for the cross talk between inflammation 
and cancer  progression92. The remarkable interrelationship of NF-κB activation to tumor progression—through 
a combination of processes including tumor cell proliferation, retarding apoptosis, accelerating angiogenesis, 
promoting pro-tumor macrophages—singularly and collectively underscore the importance of developing new 
therapeutic agents that target NF-κB both for the prevention as well as for the treatment of various human 
 cancers92,93. We have, therefore, undertaken evaluations to examine if MGF-AuNPs can efficiently suppress the 
activation of NF-κB in tumor cells. Our investigations entailed seeding PC-3 cells into 6 well plates with sub-
sequent treatment with MGF-AuNPs. These MGF-AuNPs-treated cells were subsequently post-treated with 
tumor necrosis factor alpha (TNF-α) for another 30 min at 37 °C. TNF-α, is a multifunctional pro-inflammatory 
cytokine that belongs to the tumor necrosis factor  superfamily94. The control group PC-3 cells were incubated 
with TNF-α only to stimulate NF-κB95,96. Quantification of NF-κB suppressive effects of MGF-AuNPs was car-
ried out using flow cytometry in comparison with the controls. The flow cytometry analysis, as shown in the sup-
plementary materials in Figure S6, indicated that MGF-AuNPs effectively blocked the TNF-α-induced-NF-kB 
activation in the PC-3 cells, which were pretreated with the nanomedicine agent, with subsequent post treatment 
with TNF-α. Images depicted in Figure S6 further confirmed that the NF-κB levels were indeed significantly 
higher in the PC-3 control group—which were not treated with MGF-AuNPs (Figure S6). These studies high-
light two important experimental findings that MGF-AuNPs can be used: (1) for the inhibition of NF-κB signal-
ing thereby transferring signals to the nucleus to induce corresponding gene expression, to control excessive cell 
proliferation, reduce/eliminate apoptotic resistance—all resulting in anti-angiogenesis, inhibiting invasion, and 
thus to effectively control/eliminate metastasis; and (2) in the overall design of new targeted therapeutics aimed 
at cancer prevention and therapy.
TNF-α has gained a ubiquitous “yin and yang” role in cancer development and metastases. It is well-known 
that TNF-α released from macrophages activates NF-κB-mediated signaling pathway in various cancers—thus 
playing a major role in cancer progression and  metastasis94–97. Tumor microenvironment is highly dynamic in 
cell-to-cell crosstalk between NF-κB and other signaling pathways. Such crosstalk feedback loops modulate 
the inflammatory response in macrophages by altering NF-κB  activation98. Encouraged by the NF-κB target-
ing ability of MGF-AuNPs, we reasoned the logistics of the role of this nanomedicine agent in targeting tumor 
microenvironment. A strong rationale for such investigations stemmed from the fact that tumor-associated 
macrophages (TAMs) engineer regulation of cancer growth and metastases through alterations of tumor cell 
proliferation, migration, invasion, angiogenesis, and immunosuppression. Immune cells outside the tumors 
produce pro-inflammatory cytokines to activate tumor NF-κB pathway of tumor cells and also tumor-infiltrating 
cells such as macrophages and myeloid-derived suppressor cells (MDSCs)—all resulting in a tumor-permissive 
environment for the growth and metastasis.
In the following sections, we will describe the key findings of the innate ability of MGF-AuNPs to target 
macrophages and subsequently on how the macrophage affinity of this nanomedicine agent would translate into 
the design of a new immunomodulatory prostate cancer therapeutic agent.
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Target specificity of MGF‑AuNPs toward macrophages. In our investigations, RAW264.7 cells 
were chosen over bone marrow derived macrophages (BMDMs), for two primary reasons: (1) RAW264.7 are 
developed from peritoneal macrophages and are, therefore, more diverse in macrophage population i.e., the 
macrophages come from all visceral tissues. Therefore, our overarching objective was to test if MGF-AuNPs 
can reeducate macrophages from diverse tissues so that this new nanomedicine agent can be used in treating 
tumors of different tissue origin and not just prostate tumors; (2) RAW264.7 cells are not subjected to cytokine 
stimulation, which is the case with BMDMs, that puts BMDMs slightly more on pre-activated side, which in 
turn might interfere with MGF-AuNPs ability as a macrophage re-education agent. The central hypothesis of our 
investigation was to address the ability of the nanomedicine agent, MGF-AuNPs, to re-educate macrophages to 
eliminate tumors. It is important to recognize that T cells are not involved in producing the anti-tumor effects in 
our investigations because we have used SCID mice which are deficient in T and B cells. Therefore, our in vivo 
investigations, as described in subsequent sections provide compelling evidence on the ability of MGF-AuNPs 
as a macrophage re-education immunomodulatory agent.
Macrophages are classified as non-neoplastic cells with pro-tumor or anti-tumor phenotypes depending 
on their anatomical location, and the physiological context. Classically activated macrophages (referred to 
as M1) and alternatively activated macrophages (referred to as M2) fit two extremes within the spectrum of 
the macrophage  phenotypes99. Tumor-associated macrophages (TAMs) closely resemble “alternative” (M2) 
 macrophages100. M1 macrophages are recognized as classically activated macrophages that can phagocytize 
pathogens and exert tumoricidal activity through activation of antitumor activity primarily by IL-12–dependent 
natural killer (NK) cell recruitment. On the other hand, proliferating tumors in humans exhibit polarized M2 
phenotype that are directly involved in tumor metastasis, and ultimately contributing to drug resistance of the 
 disease101. Tumor associated macrophages often express M2-like phenotype with high IL-10, high arginase-1 and 
low IL-12—all contributing to pro-tumorigenic activities. In the context of prostate cancer, there is considerable 
evidence supporting macrophage infiltrations (inflammation) which are associated with especially advanced 
stages of prostate cancer. In fact, castrated tumors possess more pro-tumorigenic M2 macrophage phenotype 
thus inducing the onset of immunosuppressive  state102–105.
It is also important to note that drugs capable of targeting NF-κB signaling in TAMs can reprogram mac-
rophages from the pro-tumor M2 to an anti-tumor M1 phenotype. This process within the TAMs promotes 
regression of advanced tumors by induction of macrophage tumoricidal activity and activation of antitumor 
activity through IL-12–dependent NK cell  recruitment106,107. Given the importance of M2 to M1 macrophage 
reeducation and the established role of MGF-AuNPs in targeting NF-κB signaling, the logical next step was 
to evaluate the macrophage targeting ability of this nanomedicine agent, especially to explore its capability in 
transforming pro-tumor M2 to an anti-tumor M1 phenotype within TAMs.
In our initial experiments, we treated the RAW 264.7 macrophages with MGF-AuNPs and evaluated for 
the endocytosis of these nanoparticles in macrophage cells. As shown in Fig. 7, indeed, MGF-AuNPs displayed 
Figure 7.  Macrophages internalize MGF-AuNPs more than PC-3 cells. (A,B) RAW 264.7 and PC-3 were 
cultured in 6 well plates for overnight. The cells were then incubated with MGF-AuNPs for 1 h followed by 
washing of the cells to remove uninternalized MGF-AuNPs. The cells were then analyzed by CytoViva dark field 
microscopy and pictures were taken.
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excellent affinity and propensity to internalize within macrophages through phagocytosis. It is important to 
note that comparison of images (Fig. 7A,B), demonstrates that, under similar experimental conditions of using 
MGF-AuNPs (40 µM) incubated for 60 min, macrophages assimilated higher payloads of MGF-AuNPs as com-
pared to PC-3 cells. Macrophages phagocytized MGF-AuNPs efficiently, whereas the PC-3 cells, which use 
laminin receptor-mediation as the primary process to internalize these nanoparticles, exhibited significantly 
lower propensity for internalization of this nanomedicine agent. Having established the macrophage-avidity 
of MGF-AuNPs, we turned our attention in testing the ability of these nanoparticles in inhibiting NF-κB phos-
phorylation in macrophages.
MGF‑AuNPs inhibit NF‑κB phosphorylation in macrophages. NF-κB is a transcription factor that 
resides in IκB kinase (IKK) complex located in the cytoplasm along with inhibitor of NF-κB proteins (IκBs), 
NF-κB activation is stimulated by TNF-α, or other cell stressors which then leads to NF-κB phosphorylation and 
translocation to the  nucleus89. This directly influences the transcription of pro-tumor genes in cancer cells and 
macrophages. The rationale for our investigations is that the NF-κB intervention in macrophages can polarize 
macrophages to the anti-tumor M1 phenotype to eliminate  tumors100. In order to evaluate the ability of MGF-
AuNPs to induce NF-κB inhibition in macrophages, we pretreated RAW 264.7 with either MGF-AuNPs or starch 
encapsulated AuNPs (Starch-AuNPs: S-AuNPs served as a control AuNPs). Our experimental findings revealed 
that MGF-AuNPs inhibited RANKL and LPS induced NF-κB in macrophages (Fig. 8E,F).
Figure 8.  MGF-AuNPs induced polarization of macrophages and inhibits NF-κB activation. (A–D) RAW 
264.7 cells were pretreated with either Starch-AuNPs (S-AuNPs as control), or MGF-AuNPs for 2 h and treated 
either with LPS (100 ng/mL) or RANKL (25 ng/mL) or left untreated for 4 h. RNA was isolated from treated and 
untreated samples and analyzed for IL-12, TNF-α, IL-10, and IL-6 by real time PCR using probes from TaqMan, 
Applied Biosystems. (E). RAW 264.7 cells were either treated with LPS (100 ng/mL) or Starch-AuNPs (S-AuNPs 
as control), or MGF-AuNPs or left untreated for 30 min. The cells were lysed with 1X Lamellae buffer and lysates 
were run on PAGE gel and transferred onto nitrocellulose membranes. The membranes were than probed for 
either phospho- NF-κB or NF-κB using respective antibodies. (F). The RAW 264.7 cells were cultured overnight 
in 6 well plates and pre-treated with different doses of MGF-AuNPs (0, 32 µg/mL) for 3 h. Subsequently the cells 
were washed and treated with LPS (100 ng/mL) for 45 min. After incubation with LPS the cells were washed, 
fixed and permeabilized. After permeabilization the cells were stained with PE conjugated anti-NF-κB antibody 
for 45 min. The cells were washed and analyzed using flow cytometry. (G) The RAW 264.7 cells were cultured 
overnight in 6 well plates and pre-treated with different doses of MGF-AuNPs (0, 32 µg/mL) for 45 min. Cells 
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MGF‑AuNPs, but not S‑AuNPs, polarize macrophages to anti‑tumor or M1 phenotype. Tumor 
microenvironment modifies the macrophages which then aid in the progression of these  tumors108. The modi-
fied macrophages or TAMs have reduced antigen presentation ability and produce elevated levels of immuno-
suppressive cytokines such as IL-10108. The macrophages within the tumor microenvironment also produce 
increased levels of antiangiogenic cytokines such as IL-6109. In order to understand the effects of MGF-AuNPs on 
macrophages, we have investigated the expression of macrophage polarizing cytokines such as IL-12, IL-10, IL-6, 
and TNF-α upon treating RAW 264.7 macrophages with MGF-AuNPs. In RAW 264.7 macrophages, which were 
treated with MGF-AuNPs, our experimental findings conclusively demonstrated elevated levels of anti-tumor 
cytokines such as IL-12 and TNF-α, while reducing the levels of pro-tumor cytokines such as IL-10 and IL-6 
(Fig. 8A–D). In contrast, the results from similar investigations using the starch-stabilized gold nanoparticles 
(S-AuNPs), we observed no macrophage targeting capability and no influence in elevating the levels of anti-
tumor cytokines such as IL-12 and TNF-α (Fig. 8). These results suggested the potential immunotherapeutic 
role of MGF-AuNPs and, therefore, prompted us to further probe into capabilities of this nanomedicine agent 
for modifying macrophages.
In order to evaluate if MGF-AuNPs can reprogram M2 macrophages into the therapeutically desirable anti-
cancer M1 phenotype, we cocultured MGF-AuNPs-pretreated macrophages with prostate tumor cells (PC-3) and 
then looked for tumor proliferation differences between this group and the control PC-3 cells which were directly 
treated with naïve macrophages only (Scheme 3). We found that macrophages transfected with the MGF-AuNPs 
agent displayed gene expression profiles similar to anti-tumor M1 phenotype. This observation is consistent with 
the significant inhibition in the proliferation of tumor cells. However, PC-3 cells that were cocultured with naïve 
macrophages failed to reduce the proliferation of PC-3 cells (Fig. 9 and Scheme 3). These data suggest that MGF-
AuNPs-mediate anti-tumor phenotype to macrophages expression and therefore warranted further investigations 
on whether this nanomedicine agent would promote elevation in the levels of anti-tumor cytokines such as IL-12 
and TNF-α while reducing the levels of pro-tumor cytokines such as IL-10 and IL-6. With this objective in mind, 
we incubated MGF-AuNPs with RAW 264.7 macrophages and analyzed the levels of various pro-tumor and anti-
tumor cytokines. Real-time PCR (Quantitative-PCR) showed robust increase in anti-tumor (pro-inflammatory) 
cytokines IL-12 (tenfold higher) and TNF-a (50-fold higher), while reducing the levels of pro-tumor cytokines 
such as IL-10 and IL-6 in macrophages treated with MGF-AuNPs. Similar experiments using the starch-stabilized 
gold nanoparticles (S-AuNPs) control showed no effects toward enhancing anti-tumor cytokines in the treated 
macrophage cells (Fig. 8). Tumor microenvironment modifies the macrophages which then aid in the progression 
Figure 9.  MGF-AuNPs-treated macrophages inhibited the proliferation of prostate tumor cells. Raw 264.7 
macrophages were pre-treated with MGF-AuNPs for 18 h. Separately, PC-3 cells were labelled with CFSE to 
assess their proliferation. The macrophages were then co-cultured with PC-3 cells for 72 h. The images were 
obtained by fluorescent microscope.
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of these  tumors102. The modified macrophages or TAMs have reduced antigen presentation ability and produce 
elevated levels of immunosuppressive cytokines such as IL-10108. The macrophages within the tumor microen-
vironment also produce increased levels of antiangiogenic cytokines such as IL-6. Therefore, our results which 
demonstrate the ability of MGF-AuNPs in promoting higher levels of anti-tumor cytokines, such as IL-12 and 
TNF-α, while reducing the levels of pro-tumor cytokines, such as IL-10 and IL-6, are significant toward proving 
the immunomodulatory intervention in prostate cancer therapy (Scheme 3).
TAMs which originate from resident macrophages from the bone marrow and spleen are key tumor stromal 
cell types and play a critical role in tumor survival, growth, and  metastasis110,111. Several investigations have con-
firmed spleen macrophages (Mφ) as the key TAM precursors, where macrophages maintain hematopoietic steady 
state by engulfment of neutrophils and  eosinophils112. Tumor microenvironment modifies the macrophages 
which then aid in the progression of these tumors. The modified macrophages or TAMs have reduced antigen 
presentation ability and produce elevated levels of immunosuppressive cytokines such as IL-10. The macrophages 
within the tumor microenvironment also produce increased levels of antiangiogenic cytokines such as IL-6. It 
is important to understand how enhanced retention of MGF-AuNPs in spleen affects macrophage function.
In order to explore the ability of MGF-AuNPs to target splenic macrophages, we have undertaken a detailed 
biodistribution study of MGF-AuNPs in normal mice as discussed below.
Targeting splenic macrophages. Spleen is a critical secondary lymphoid organ showing abundance 
of B cells, T cells, NK cells, and is also a reservoir of mononuclear phagocyte system (MPS), mainly resident 
 macrophages113. Recent investigations have shown that the local and systemic immune response to cancer 
increases by the ability of drugs or nanoparticles to target splenic macrophages which comprise mostly of 
M2-like pro-tumor  macrophages114. Macrophage position and function in splenic domains confer them unique 
 phenotypes115. Suzuki et al. have shown that Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid 
suppressor cells in tumor-bearing animals and enhances antitumor immune  activity116. Indeed, the superior 
antitumoral efficacy of Trabectedin (Yondelis) has been attributed to the ability of this drug to target splenic 
macrophages thus exerting TAM selective cytotoxic activity towards  Ly6Chigh monocytes in circulation and in 
the  spleen117. In order to evaluate further on the macrophage targeting ability and immunomodulatory char-
acteristics of MGF-AuNPs, we have performed systemic administration via intravenous injection in mice—all 
aimed at testing if this nanomedicine agent is effective in targeting splenic macrophages. We discuss here com-
pelling evidence from murine models of cancer in support of macrophage-targeted intervention strategies with 
Scheme 3.  Targeting ability of MGF-AuNPs toward tumor microenvironment (TME) and it’s reprograming 
ability of M2 to M1 phenotype.
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the potential of MGF-AuNPs for use in dramatically reducing prostate and various other cancer morbidities 
through immunomodulatory mechanisms.
In order to understand the pharmacokinetics/ pharmacodynamics of MGF-AuNPs, we have evaluated the 
uptake of gold nanoparticles, in vivo, in normal mice as well as in prostate tumor-bearing mice. These studies 
were performed by first producing the radioactive equivalent of MGF-AuNPs using 198Au isotope because the 
gamma emission (0.411 MeV) of 198Au isotope allows scintigraphic counting of radioactivity of gold for accurate 
estimation of the nanomedicine agent in various  organs39. Post administration of radioactive MGF-198AuNPs, 
in normal mice, through intravenous delivery, we analyzed for the presence of gold in various organs at various 
time points using scintigraphy counting (Fig. 10A)39. Further quantification of gold nanoparticles in spleen, liver 
and tumors were performed through neutron activation analysis (NAA) of various organs post administering 
specific amounts of MGF-AuNPs (Fig. 10B). Our results, as shown in Fig. 10A,B, showed a significant uptake of 
MGF-198AuNP in spleen. This observation is clearly in stark contrast to a vast variety of gold nanoparticles, which 
generally show hepatobiliary uptake in  liver34,118. Together with these results, we infer the inherent propensity 
of MGF-AuNPs to target splenic macrophages.
It may be noted that the mode of delivery, going from the intravenous to intraperitoneal, did not reduce 
the uptake of MGF-AuNPs in splenic macrophages. The preferential accumulation in liver and spleen invoked 
the possibility of this nanomedicine agent to target splenic macrophages. In order to elucidate if the uptake of 
MGF-AuNPs in spleen is indeed of splenic macrophage origin, we have performed further in vivo investigations 
using severely combine immune-deficient (SCID) mice. The rationale for this animal model is based on the 
fact that SCID mice manifest active macrophages while lacking in T and B  cells119. Before moving onto in vivo 
tumor studies with MGF-AuNPs, we tested the toxicity of this nanomedicine agent on SCID mice. The doses of 
MGF-AuNPs, at which prostate tumors are suppressed in vivo, caused no systemic toxicity in normal mice as 
elucidated through detailed toxicity studies (see supplementary materials section). Intraperitoneal administration 
of MGF-AuNPs in SCID mice resulted in preferential accumulation in liver and spleen which further suggested 
that MGF-AuNPs might be assimilated by splenic macrophages (Fig. 10). Macrophages play important role in 
tumor development by supporting vascularization of tumors as well as inhibition of subsequent generation of 
tumor specific cytokines. It is well-known that macrophages migrate to spleens to phagocytize dead RBCs, and 
therefore, the accumulation of MGF-AuNPs in spleen, as observed, suggests the selective accumulation of this 
nanomedicine agent in the macrophages.
Figure 10.  MGF-AuNPs preferentially accumulate in spleens of SCID mice: (A) Biodistribution of MGF-
198AuNPs in normal mice showing selective uptake only in liver and spleen and limited/no uptake in non-target 
organs; (B) Biodistribution of MGF-AuNPs in prostate tumor bearing SCID mice. Gold concentrations in 
tumor, liver and spleen measured using neutron activation analysis (NAA)—showing limited uptake in tumors 
and major uptake in spleen and liver—suggesting targeting of MGF-AuNPs on splenic macrophages.
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The in vivo distribution of MGF-AuNPs in SCID and normal mice, which revealed high percentage of accu-
mulation of MGF-AuNPs in spleen, suggested possible macrophage-based internalization. Macrophage position 
and function in splenic domains confer them unique phenotypes thus corroborating tumor killing properties 
of MGF-AuNPs-pretreated macrophage cells, as observed in the co-culture experiments involving PC-3 cells 
(Fig. 9 and Scheme 3). These experimental findings are of significance because they lend experimental evidence 
on the unique characteristic of this nanomedicine agent to exploit trophic macrophages to subvert innate and 
adaptive immune responses capable of destroying malignant cells.
Targeting NF-κB signaling pathway, induction of polarization of macrophages to anti-tumor phenotype by 
inhibiting NF-κB phosphorylation, ability to promote the levels of anti-tumor cytokines, such as IL-12 and TNF-
α, as discussed above—individually and collectively—infer the immunomodulatory features of MGF-AuNPs. 
In vivo therapeutic efficacy studies of MGF-AuNPs in tumor model was an obvious next step to evaluate whether 
the various immunomodulatory parameters, as observed in vitro, would be translated under the more complex 
in vivo tumor profiles in tumor bearing mice. We have therefore, undertaken detailed therapeutic efficacy of 
MGF-AuNPs in prostate tumor bearing SCID mice as discussed below.
Therapeutic efficacy of MGF‑AuNPs in treating prostate tumor. We have used severe combined 
immunodeficient (SCID) male mice bearing a flank model of human prostate cancer, derived from a subcuta-
neous implant of 10 million PC-3 cells, for the therapeutic efficacy and pharmacokinetic studies. In our evalu-
ations, unilateral solid tumors were allowed to grow for three weeks, and animals were randomized (denoted 
Day 0) into control and treatment groups (n = 7) with no significant differences in tumor volume (0.0076 ± 0.08 
to 0.0083 ± 0.04  cm3). In vivo dosing involved administering on day 0 three doses of MGF-AuNP (0.5 mg/kg 
bw, 1.0 mg/kg bw and 1.5 mg/kg bw—in 100 μL Dulbecco’s PBS) intraperitoneally, while the control SCID mice 
received only 100 μL Dulbecco’s PBS/saline. This treatment regimen was performed twice per week. Tumors 
were then measured twice each week until the end of the study (Day 42). Figure 11 shows results from the MGF-
AuNPs-treated human prostate cancer bearing SCID mice. Within two weeks (Day 14), tumor growth in the 
treated animals started slowing down with respect to the control animals. Day 17, post administration of MGF-
AuNPs (1.5 mg/kg bw), tumor volumes were two-fold lower (p < 0.005) for treated animals as compared to the 
control group. Three weeks, post administration of after MGF-AuNPs (1.5 mg/kg bw), tumor volumes for the 
control animals were fully six-fold greater with respect to those for the MGF-AuNPs-treated group (p < 0.0001; 
0.37 ± 0.05 vs. 0.06 ± 0.02  cm3)—suggesting > 85% reduction in the overall tumor volume for the treated group. 
This significant therapeutic effect was maintained throughout the 42 days long study. Tumors harvested from the 
treatment group consisted largely of necrotic tissue, indicating extensive death of tumor cells.
Figure 11.  MGF-AuNPs inhibit PC-3 tumor growth in SCID mice. The SCID mice were divided in groups of 
seven mice each and implanted with PC3 cells subcutaneously in the right flanks. The tumors were allowed to 
grow till visible and palpable. Once palpable, the mice were randomized and treated with MGF-AuNPs (0.5 mg/
kg, 1.0 mg/kg and 1.5 mg/kg body weight). These experiments were terminated once the untreated control mice 
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Interestingly, biodistribution studies suggested that very low percentage of MGF-AuNPs reached the tumor 
tissue while most of the therapeutic agent was found in the spleen (Fig. 10). It is important to note that SCID 
mice lack T and B cells which are needed for the growth of human prostate tumors. In this context, the remark-
able therapeutic efficacy, as shown in Fig. 11, therefore, suggests the ability of MGF-AuNPs to target the tumor 
microenvironment and, thus ensue modification of macrophages as the primary mode of therapeutic action of 
this nanomedicine agent.
The above data provides experimental validation to our hypothesis that MGF-AuNPs reeducate the mac-
rophages to eliminate the tumors. It may be noted that the initial antitumor response is based on macrophages 
direct interaction with tumor cells and inflammatory cytokine release. These macrophages, after initial interac-
tion with tumor cells, present antigens to T cells. Tumors in most cases modify the macrophages, which then 
help in progression of these tumors and suppress the secondary immune response. Therapeutic efficacy data, in 
conjunction with immunomodulatory characteristics as discussed in previous sections, demonstrate that our 
new therapeutic agent MGF-AuNPs can restore that balance where macrophages reeducation can lead to tumor 
growth inhibition. However, in our future investigations, we will be evaluating the effect of MGF-AuNPs on 
tumor inhibition using immune-sufficient mice.
The compelling therapeutic efficacy data, as summarized above, was further corroborated through evalu-
ation of angiogenesis inhibitory effects of MGF-AuNPs in vivo. Angiogenesis is ubiquitous in tumor growth, 
invasion, progression, and metastasis of a vast majority of human  cancers120. Therefore, targeting this process 
may potentially halt the growth and spread of  cancers121. Some of the prominent FDA approved angiogenesis 
inhibitors currently used in cancer therapy (with their mode of action) include: Bevacizumab (VEGF-A anti-
body); Ramucirumab (VEGFR2 antibody); Sunitinib (Tyrosine Kinase Inhibitor); Sorafenib (Tyrosine Kinase 
Inhibitor); Pazopanib (Tyrosine Kinase Inhibitor); Lenvatinib (Tyrosine Kinase Inhibitor); and Cabozantinib 
(Tyrosine Kinase Inhibitor)121. Angiogenesis inhibitors act through direct interference in blood vessel growth. 
A well-established mode of action of angiogenesis inhibitors manifests binding to VEGF and/or its  receptors122. 
Angiogenesis inhibitors are also known to bind to various cell surface receptors, VEGF receptors 1 and 2 which 
participate in angiogenesis, or they block blood vessel growth through strong and selective binding interactions 
with proteins in the downstream signaling pathways. Our rationale behind these studies stemmed from a variety 
of immunomodulatory features of MGF-AuNPs, as discussed in the preceding sections. There is considerable 
experimental evidence supporting that angiogenesis inhibitors are immunomodulatory and are capable of sup-
pressing tumor  growth123 immune system.
Inhibition of angiogenesis in vivo. The compelling immunomodulatory effects, in controlling growth of 
tumors in vivo, prompted us to investigate the effects of MGF-AuNPs on angiogenesis in tumor tissues obtained 
through in vivo therapeutic efficacy experiments as discussed above. These studies were performed through 
immunostaining using the CD31 antibody because it has high specific affinity for vascular endothelial cells. 
Twelve fields (at 400x), from each prostate tumor xenografts, were analyzed to determine the average number 
of vessels per field (micro-vessel density = MVD). The findings from these studies indicated a significant reduc-
tion of MVD in samples collected from the MGF-AuNPs (1.5 mg/kg bw) treated animals as compared to the 
control group (saline treated) (Figure  S7A–C). Manifestation of angiogenesis in MGF-AuNPs-treated tumor 
tissues, taken in concurrence with a plethora of immunomodulatory data discussed above, infers the immu-
nomodulatory angiogenesis inhibitor characteristics of this nanomedicine agent exerting stimulatory effects on 
the immune system.
Conclusions
Our studies lend credible experimental evidence demonstrating that inhibition of the receptor activator of NF-κB, 
by the new nanomedicine agent MGF-AuNPs, prevents prostate cancer development. The ability of MGF-AuNPs 
to target NF-κB signaling pathway will provide an attractive therapeutic strategy for the treatment of various 
forms of advanced cancers. As a vast majority of patients with solid tumors require therapeutic approaches with 
capabilities to reprogram the local immunosuppressive tumor milieu in order to revive antitumor immunity, 
detailed immunotherapeutic investigations, and results reported herein, provide compelling evidence on mac-
rophage targeting abilities of the new MGF-AuNP nanoceutical. Our pre-clinical in vitro and in vivo studies have 
shown that MGF-AuNPs effectively target tumor-associated macrophages (TAMs) which abundantly infiltrate 
most solid tumors. TAMs-targeting strategies of MGF-AuNPs have been effectively used to initiate macrophage 
re-education from pro tumor M2 macrophages to antitumor M1 phenotype—thus eliminating cancer cells, 
restrict tumor growth and metastasis. Overall, our green nanotechnology discoveries, which have resulted in the 
development of a new generation of phytochemical-encapsulated nanomedicine agent (MGF-AuNP), provide 
further new insights on the therapeutic potential of TAM targeting nanoceuticals to improve immunotherapies.
Methods
Materials. Mangiferin, Sodium tetrachloroaurate (III) dihydrate, MTT (3-(4,5-dimethyl thiazol-2-yl)-
2,5-diphenyl tetrazolium), dynasore reagent and Chlorpromazine (CPZ) were obtained from Sigma (St. Louis, 
MO, USA). RPMI, fetal calf serum, TryplE, Trypan blue, DAPI (4′,6-diamidino-2-phenylindole), 2,7-dichloro-
fluorescin diacetate (DCFH-DA), mouse IgG isotype control, and laminin receptor antibody  (MLuC5) were 
obtained from ThermoFisher Scientific, USA. FITC Annexin V Apoptosis Detection Kit was obtained from BD 
Pharmingen, USA. X-22 anti-clathrin antibody (ab2731), anti-Caveolin-1 antibody (ab2910), anti-fibronectin 
antibody (ab18265), and in vitro angiogenesis assay kits (ab204726) were obtained from Abcam, USA. GFP-
CERTIFIED Apoptosis/ Necrosis detection kit (ENZ-51002) was obtained from Enzo Life Sciences, Inc., USA. 
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Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb (Alexa Fluor488 Conjugate) Kit was obtained from Cell Sign-
aling Technology, USA. Double distilled water was used throughout the experiment.
Cell lines. The human prostate cancer (PC-3), human aortic endothelial cells (HAECs), and mouse mac-
rophages (RAW 264.7) cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, 
VA), and cultured by the University of Missouri Cell and Immunobiology Core facility using procedures recom-
mended by ATCC. Recent gene therapy results, using in vitro and in vivo models, unequivocally suggest that 
PC-3 cells are excellent models for investigations related to drug targeting approaches for treating castration-
resistant prostate cancer (CRPC)124–131.
Synthesis of Mangiferin conjugated gold nanoparticles (MGF‑AuNPs). The Mangiferin gold nan-
oparticles (MGF-AuNPs) were produced by mixing of 4.2 mg mangiferin (MGF) in 6 mL of doubly deionized 
(DI) water. The solution was stirred at 100 °C for 10 min to dissolve the MGF into water to get a clear  solution132. 
Sodium tetrachloroaurate (100 µL of 0.1 M) was added to the reaction mixture to produce gold nanoparticles 
(AuNPs). Change in color from yellow to burgundy wine red indicated the formation of MGF-AuNPs in the 
homogeneous reaction mixture. The MGF-AuNPs were characterized by various instrumentation techniques 
including, UV–Vis  spectrophotometry133, Zetasizer Nano S90,  TEM134 and ICP-MS135. For various in vitro and 
in vivo investigations, the treatment concentrations were calculated based on the amount of gold present in 
MGF-AuNPs. The amount of Au was calculated by ICP-MS  technique136.
Cellular internalization and trafficking pathway. The endocytosis mode of MGF-AuNPs was inves-
tigated by pre-blocking various receptors onto PC-3 cells. The optimum dose and incubation time were deter-
mined by incubating PC-3 cells with various concentrations of Mangiferin conjugated gold nanoparticles (MGF-
AuNPs) at different time points. Further, the cell trafficking pathway of MGF-AuNPs was evaluated by using 
various receptor blocking agents to confirm the clathrin and or caveolae mediated endocytosis. Chlorpromazine 
(CPZ) and X-22 anti-clathrin antibodies were chosen to inhibit clathrin-mediated endocytosis. Anti-Caveolin-1 
antibody was chosen to block/inhibit caveolae-mediated uptake. Internalization of MGF-Gold nanoparticles 
were monitored by two independent techniques: (i) Cytoviva dark field fluorescence microscopy and; (ii) trans-
mission electron microscopy (TEM)134. For the dark field microscopic study, ultra clean and sterile cover slip 
was kept in 6 well plate to grow the PC-3 cells. For the study by TEM  technique134, cells were grown on the plate 
without any coverslip.
Briefly, PC-3 cells  (106/mL) were seeded into 6 well plates in RPMI medium and incubated for 24 h in  CO2 
incubator at 37 °C. The cells were pre-incubated with the inhibitors as follows: PBS (control), chlorpromazine 
hydrochloride (10 µM; 20 min), X-22 anti-clathrin antibody (3 µg/mL; 60 min), anti-caveolin-1 antibody (3 µg/
mL; 60 min), mouse IgG isotype control (10 µg/mL; 60 min), anti-fibronectin antibody (3 µg/mL; 60 min), and 
laminin receptor antibody (ABLR) (10 µg/mL; 60 min). The cells were incubated with all the inhibitors in  CO2 
incubator at 37 °C. Post incubation, cells were washed with 1XPBS twice followed by incubation with MGF-
AuNPs (41 µM) for 60 min in the  CO2 incubator at 37 °C. The samples were prepared by the following techniques:
Dark field microscopic technique. After incubation, cells were washed 10 times with 1X PBS, and fixed 
with 4% paraformaldehyde (PFA) for 10 min in the  CO2 incubator at 37 °C. Cells were further washed 2 times 
with 1X PBS and slides were prepared by using DAPI nuclear dye and observed under CytoViva dark field 
microscope coupled with dual mode fluorescence. Cell morphology was initially observed, followed by the 
uptake of nanoparticles. Images were captured via Dage Imaging Software.
TEM technique. After incubation, cells were washed 10 times with 1X PBS, trypsinized and centrifuged 
into pellets, and fixed with 2% glutaraldehyde, 2% paraformaldehyde in sodium cacodylate buffer (0.1 M). The 
cells were further fixed with 1% buffered osmium tetroxide in 2-Mercaptoethanol buffer and dehydrated in 
graded acetone series and embedded in Epon-Spurr epoxy resin. Sections were cut at 85 nm using a diamond 
knife (Diatome, Hatfield PA). The sections were stained with Sato’s triple lead stain and 5% aqueous uranyl ace-
tate for organelle visualization. The samples, as prepared above, were examined on JEOL 1400 TEM microscope 
(JEOL, Peabody, Mass.) operated at 80 kV at the University of Missouri’s Electron Microscopy Core  Facility134.
MGF-AuNPs were explored for their selective affinity toward tumor cells by incubating with the same con-
centrations and time points as used for the normal endothelial cells (HAECs).
Cell viability assay. The effect of MGF-AuNPs on prostate cancer (PC-3) and normal human aortic 
endothelial (HAECs) cells viability was determined using MTT assay (Sigma) over a period of 48 and 72 h. The 
intensity of developed color was measured by micro plate reader (Molecular device, USA) operating at 570 nm 
wavelength. Percent cell viability was calculated by using the formula: (T/C) × 100, where C = Absorbance of 
control, T = Absorbance of treatment. The IC-50 values were calculated using the Origin  software137. Starch 
stabilized gold nanoparticles (S-AuNPs) as well as Gum-Arbaic stabilized gold nanoparticles (GA-AuNPs) were 
used as control NPs group for the in vitro experiments in all the cell viability assay to demonstrate minimal/no 
effect of control group on the cells.
Apoptosis assay. PC-3 cells were incubated with MGF-AuNPs for 24 h and the experiment was performed 
according to the manufacture’s protocol (FITC Annexin V Apoptosis Detection Kit I). The samples were ana-
20
Vol:.(1234567890)
Scientific Reports |        (2021) 11:16797  | https://doi.org/10.1038/s41598-021-96224-8
www.nature.com/scientificreports/
lyzed by FACScan flow cytometry (FACSort, Becton Dickinson, USA). For each sample, 30,000 ungated events 
were  acquired138.
Assessment of apoptotic and necrotic cell morphology. PC-3 cells were incubated with MGF-
AuNPs for 24 h and the experiment was performed according to the manufacture’s protocol (GFP-CERTIFIED) 
Apoptosis/ Necrosis detection kit). Briefly, the PC-3 cells after treatment with either MGF-AuNPs or Stauro-
sporin were incubated with the apoptosis and necrosis detection reagent for 10 min. The slides were prepared 
and visualized under fluorescent microscope with a dual filter set for Cyanine-3 (Ex/Em: 550/570 nm), 7-AAD 
(Ex/Em: 546/647) and GFP/FITC (Ex/Em: 488/514) (Olympus, USA).
In vitro anti‑angiogenesis assay. In vitro anti-angiogenesis effect of MGF-AuNPs on HAECs cells was 
determined using tube formation assay. The test was performed according the manufacture’s protocol (In vitro 
angiogenesis assay kit). Briefly, matrigel was coated in 96 well plate and the plates were incubated for 30 min at 
37 °C. HAECs cells and test samples were added into the same plates and incubated for 24 h for tube formation 
analysis. The images were captured by fluoresce microscope, (Olympus, Center Valley, PA, USA) at 4 × magni-
fication after 24  h139.
NF‑κB measurement. The Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb (Alexa Fluor488 Conjugate 
(catalog number 3033) Kit was used to study the effect of MGF-AuNPs on the expression of NF-κB. Briefly, PC-3 
cells were seeded into 6 well plate at a density of  106 cells/mL and were incubated for 24 h. The cells were treated 
with MGF-AuNPs (40 µM) for 18 h and post-treated with TNF-α (0.1 nM) for another 30 min at 37 °C. The 
assay was performed as per kit instructions and the results were analyzed by FACScan flow cytometry (FACSort, 
Becton Dickinson, USA) with a minimum of 10,000 events being recorded.
Macrophage MGF‑AuNPs uptake studies. RAW 264.7 macrophages were cultured in DMEM + 10% 
FBS in a 75  cm2 flask. The cells at a density of  106 were plated in 6 well plates overnight for adherence. The cells 
were then replenished with fresh medium and incubated with MGF-AuNPs (40 µM) for 60 min. Cells were then 
analyzed for the presence of gold nanoparticles by CytoViva dark field microscopy.
The effect of MGF‑AuNPs on NF‑κB inhibition in RAW 264.7 macrophages. Cells were preincu-
bated with MGF-AuNPs for 2 h followed by treatment with either LPS (100 ng/mL-positive control) or RANKL 
(10 ng/mL) for 30 min. Cells were lysed and lysates were run on polyacrylamide gel electrophoresis and trans-
ferred onto nitrocellulose membrane. These membranes were then probed with phospho-NF-κB antibody and 
NF-κB from Cell Signaling  Technologies140.
Flow cytometry for NF‑κB in RAW macrophages. RAW 264.7 cells (a murine monocyte/macrophage 
cell line, ATCC) were plated in 6-well culture plates in DMEM culture media (Gibco) supplemented with 10% 
fetal calf serum (Sigma-Aldrich) and 1% penicillin–streptomycin and stored overnight at 37 °C and 5%  CO2. 
The confluent macrophages were then pre-treated with different doses of MGF-AuNPs (0, 8, 16, and 32 µg/mL) 
and S-AuNPs (32 µg/mL) for 3 h. Subsequently the cells were washed with DMEM (1%FBS 1% P/S) to remove 
uninternalized nanoparticles and then treated with LPS (100 ng/mL) or TNF-α (20 ng/mL) for 45 min in DMEM 
(1% FBS 1% P/S). After incubation with LPS or TNF-α, the cells were suspended by scraping and transferred to 
5 mL round-bottom polystyrene tubes (Falcon). The collected samples were centrifuged at 1500 rpm for 5 min, 
the supernatant was removed, and the cells were fixed with 4% paraformaldehyde in PBS for 15 min at room 
temperature. The cells were then washed in PBS, centrifuged at 1500 rpm for 5 min, and the supernatant was 
decanted. The cells were permeabilized for 30 min at room temperature in 90% methanol. After permeabiliza-
tion, the cells were washed and incubated in 100μL of anti-NF-κB p65 (Ser536) antibody (Cell Signaling, 5733) 
at 1:50 dilution for 1 h at room temperature in the dark. Samples were centrifuged at 1500 rpm for 5 min, washed 
with 2 mL of 1% FBS PBS. Flow cytometry data was acquired using the BD LSRFortessa X-20 Flow Cytometer 
and analyzed using Flowjo software.
Cytokine analysis by real time PCR following treatment of RAW 264.7 cells with 
MGF‑AuNPs. RAW 264.7 cells were cultured in 6 well plates overnight for adherence followed by the treat-
ment with MGF-AuNPs for 4 h. LPS and Starch stabilized AuNPs (S-AuNPs) were used as positive and negative 
control respectively. The cells were lysed, and RNA was isolated using RNA isolation kit from Qiagen (German-
town, MD). RNA was then analyzed for IL-12, TNF-α, IL-10 and IL-6 using real time  PCR141.
Effect of MGF‑AuNPs treated macrophages on prostate cancer cell proliferation. PC-3 cells at 
a density of  105 cells/well were plated in 6 well plate overnight for adherence. Subsequently, RAW 264.7 mac-
rophages were treated with MGF-AuNPs (4 µM) for 18–24 h. The macrophages were washed to remove unbound 
MGF-AuNPs in order to avoid the direct effect of MGF-AuNPs on cancer cells. In the meantime, the PC-3 cells 
were labelled with carboxyfluorescien succinimidyl ester (CFSE) to assess their proliferation. The macrophages 
were then co-cultured with PC-3 cells using a ratio of 10:1 (1 part of PC-3 cells to 10 part of macrophages) for 
72 h. The co-culture was observed under the fluorescent microscope and pictures taken. We observed significant 
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Animal studies. All in vivo work has been performed at an IACUC approved laboratory and in accordance 
with ARRIVE guidelines for animal welfare.
Ethics declarations. All experiments of MGF-AuNPs involving animals were approved by the Institutional 
Animal Care and Use Committees of the Harry S. Truman Memorial Veterans Hospital and the University of 
Missouri and were performed in accordance with the Guide for the Care and Use of Laboratory Animals under 
an IACUC approved protocol number 8767. Severe combined immuno-deficient SCID (ICR-SCID) male mice 
show a severe combined immunodeficiency (from Taconic Farms, Hudson, New York) were used for the thera-
peutic study. The mice used in our investigations weighed 24–27 g.
Description of animal procurement, housing, and grouping. Animals were maintained on a 12 h 
light–dark cycle and had access to sterilized standard chow and water ad libidum. Animals were allowed to 
acclimate for 7–10 days prior to initiation of work. Human prostate cancer cell line PC-3 was obtained from the 
American Type Culture Collection (ATCC; Manassas, VA), and cultured according to ATCC recommendations 
by the University of Missouri Cell and Immunobiology Core facility. Small Cell Neuroendocrine Carcinoma 
(SCNC) is a hormone resistant aggressive cancer which does not respond to classic androgen therapy. PC-3 is a 
SCNC cell line which is highly metastatic and does not express classic hormone receptors and hence are resistant 
to hormone therapy. Moreover, the patients treated with hormone therapy tend to relapse of  SCNC143–145. Mice 
received ear tag identifiers under inhalational anesthesia (isoflurane/oxygen) followed by unilateral, subcutane-
ous hind flank inoculations of 10 ×  106 PC-3 cells suspended in 0.1 mL of sterile Dulbecco’s phosphate buffered 
saline (DPBS) and Matrigel (2:1, v:v). Solid tumors were allowed to develop over a period of 3  weeks, and 
animals were randomized (Day 0) into control and treatment groups (n = 7) having no significant difference in 
tumor volumes (p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes were estimated from caliper 
measurements using the formula V = length × width × depth. On Day 8, animals in the treatment group received 
intraperitoneal administrations of MGF-AuNP agent in DPBS (100 μL) while under inhalational anesthesia in 
doses as outlined in the following section. Similarly, control animals received 30 μL of saline intraperitoneally. 
No significant difference (p = 0.93) in tumor volume or body weight (p = 0.21) was noted between the groups. 
Tumor volumes, body weights and health status were then determined twice each week. At the end of the study 
(Day 42), mice were euthanized by cervical dislocation, and blood sample was collected by cardiac puncture. 
Samples of spleen, liver, tumor, and blood were harvested, weighed and submitted to the University of Missouri 
Neutron Activation Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the 
accurate quantification of gold in various tissues by NAA analysis.
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a 
xenograft model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as 
we are studying prostate cancer, the use of male mice only is appropriate.
In vivo bio‑distribution study by neutron activation analysis (NAA). To assess the gold content in 
various tissue in SCID mice (n = 7). 1.5 mg/ kg bw of MGF-AuNPs were administered in these mice for seven 
weeks, while control mice (n = 7) did not receive any treatment with MGF-AuNPs. Tumor tissue, spleen, liver 
and blood were harvested upon euthanization, put into chloridometer sample vials and dried for approximately 
48 h at 100–120 °C. Dried tissue mass of approximately 0.5–1.0 g was placed into polyethylene vials (used for 
control of counting geometry). We estimated the amount of gold in various tissue samples as described previ-
ously through neutron activation analysis (NAA)  techniques38.
In vivo therapeutic efficacy study. Antitumor efficacy of MGF-AuNPs was evaluated by using prostate 
tumor xenografts in SCID mice as developed above. Briefly, SCID male mice were subcutaneously inoculated 
with 10 ×  106 PC-3 cells (suspended in 0.1 mL of sterile DPBS and Matrigel (2∶1, v:v)) in the right hind flank under 
inhalation anesthesia (isoflurane/oxygen). After inoculation, tumors were allowed to grow for 2–3  weeks, at 
which time the tumors were measured by digital caliper measurements and calculated as length × width × height. 
The mice were randomly divided into four groups (n = 7/group) with no significant difference in tumor volume, 
randomization was generated using the standard = RAND() function in Microsoft Excel, and the day of rand-
omization was considered the day zero of therapy study (Table 1). On day zero, mice were given intraperitoneal 
injections as follows: Group 1: saline treated (100 μL); Group 2: MGF-AuNPs treated (0.5 mg/kg bw); Group 
3: MGF-AuNPs treated (1.0 mg/kg bw) and Group 4: MGF-AuNPs treated (1.5 mg/kg bw)—all in 100 μL Dul-
becco’s PBS. Using this regimen, animals were treated twice per week until the end of the study (42 days). The 
animals were monitored for their tumor volume, body weight and health effects until they were sacrificed at the 
end of the study. The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a 
control for complete blood count (CBC) values and body weight measurements. Animals were sacrificed at the 
end of study. Measurement of tumor volumes were carried out twice each week until the end of the study (Day 
42).
The tissues (spleen, liver, tumor tissue and blood) were isolated from prostate tumor xenografts and were 
submitted to the University of Missouri Neutron Activation Analysis (NAA) facility at the University of Missouri 
Research reactor (MURR) for the accurate quantification of gold in various tissues by NAA analysis.
Statistical analysis. All experimental data are described as mean ± SEM. Statistical analysis was carried 
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Items Recommendation Our response with section/line number or reason for not reporting
Study design
1. For each
experiment provide brief details of study 
design including:
(a) The groups being compared, including 
control groups. If no control group has 
been used, the rationale should be stated
(b) The experimental unit (e.g. a single 
animal, litter, or cage of animals)
1. Full details of in vivo Therapeutic efficacy Studies Design (a and b):
All in vivo work has been performed at an IACUC approved laboratory and in accordance with ARRIVE guidelines 
for animal welfare. Animal studies were approved by the Institutional Animal Care and Use Committees of the Harry 
S. Truman Memorial Veterans Hospital and the University of Missouri and were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals under an IACUC approved protocol number 8767
We have over three decades of experience in conducting hypothesis driven cancer research with in vivo models using 
tumor bearing SCID mice to minimize discomfort and adverse effects in study animals (both control and treated 
animals). Here are a few representative publications where we have outlined similar in vivo investigations which have 
been accepted by the global scientific peers:
(1) Ravi Shukla, Nripen Chanda, and Kattesh V. Katti et al.: 198AuNP-EGCg for prostate cancer therapy: Proceedings 
of the National Academy of Sciences Jul 2012, 109 (31) 12426–12431; https:// doi. org/ 10. 1073/ pnas. 11211 74109
(2) Nripen Chanda, Vijaya Kattumuri, Kattesh V. Katti, et al.: Bombesin functionalized gold nanoparticles show 
in vitro and in vivo cancer receptor specificity: Proceedings of the National Academy of Sciences May 2010, 107 (19) 
8760– 8765; https:// doi. org/ 10. 1073/ pnas. 10021 43107
(3) Nripen Chanda, Para Kan, Kattesh V. Katti, et al.; Radioactive gold nanoparticles in cancer therapy: therapeutic 
efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing mice: Nanomedicine: Nanotechnology, 
Biology and Medicine, Volume 6, Issue 2, 2010, Pages 201–209,   ISSN 1549-9634, https:// doi. org/ 10. 1016/j. nano. 
2009. 11. 001
Brief description of in vivo investigations: Male SCID mice (4–5 weeks of age; Taconic Farms, Hudson, NY) were 
housed in a temperature and humidity-controlled pathogen-free barrier facility
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a xenograft 
model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as we are studying 
prostate cancer, the use of male mice only is appropriate
Description of animal procurement, housing, and grouping: Animals were maintained on a 12 h light–dark cycle and 
had access to sterilized standard chow and water ad libidum. Animals were allowed to acclimate for 7–10 days prior 
to initiation of work. Human prostate cancer cell line PC-3 was obtained from the American Type Culture Collection 
(ATCC; Manassas, VA), and cultured according to ATCC recommendations by the University of Missouri Cell and 
Immunobiology Core facility. Mice received ear tag identifiers under inhalational anesthesia (isoflurane/oxygen) fol-
lowed by unilateral, subcutaneous hind flank inoculations of 10 ×  106 PC-3 cells suspended in 0.1 mL of sterile Dul-
becco’s phosphate buffered saline (DPBS) and Matrigel® (2:1, v:v). Solid tumors were allowed to develop over a period 
of 3 weeks, and animals were randomized (Day 0) into control and treatment groups (n = 7) having no significant 
difference in tumor volumes (p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes were estimated 
from caliper measurements using the formula V = length × width × depth. On Day 8, animals in the treatment group 
received intraperitoneal administrations of MGF-AuNP agent in DPBS (100 µL) while under inhalational anesthesia 
in doses as outlined in the following section. Similarly, control animals received 100 µL of saline intraperitoneally. 
No significant difference (p = 0.93) in tumor volume or body weight (p = 0.21) was noted between the groups. Tumor 
volumes, body weights and health status were then determined twice each week. At the end of the study (Day 42), 
mice were euthanized by cervical dislocation, and blood sample was collected by cardiac puncture. Samples of spleen, 
liver, tumor, and blood were harvested, weighed and submitted to the University of Missouri Neutron Activation 
Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the accurate quantification of 
gold in various tissues by NAA analysis
Sample size
2
(a) Specify the exact number of experi-
mental units allocated to each group, and 
the total number in each experiment. Also 
indicate the total number of animals used
(b) Explain how the sample size was 
decided. Provide details of any a priori 
sample size calculation, if done
Details of Sample Size with descriptions for a and b: As outlined above, SCID mice were randomly divided into four 
groups (n = 7/group) with no significant difference in tumor volumes
On day zero, mice were administered intraperitoneal injection of MGF-AuNP agent in DPBS (100 µL) (or saline for 
the control group) as follows:
Group 1-saline treated;
Group 2-MGF-AuNPs treated (0.5 mg/kg bw); Group 3-MGF-AuNPs treated (1.0 mg/kg bw); Group 4-MGF-AuNPs 
treated (1.5 mg/kg bw)
The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a control for the evalua-
tion of complete blood count (CBC) values and body weight measurements. Animals were subjected to vaporizer 5% 
isoflurane and sacrificed at the end of study (Day 42)
The above-mentioned sample size is based on consultations with our biostatistician who confirmed that a n = 7 in dif-
ferent treatment and control groups, as elaborated above, would provide scientifically credible statistical significance 




(a) Describe any criteria used for including 
and excluding animals (or experimental 
units) during the experiment, and data 
points during the analysis. Specify if these 
criteria were established a priori. If no 
criteria were set, state this explicitly
(b) For each experimental group, report 
any animals, experimental units or data 
points not included in the analysis and 
explain why.  If there were no exclusions, 
state so
(b) For each analysis, report the exact value 
of n in each experimental group
Inclusion criteria: On the choice of the animal model, we have used Male SCID mice in our investigations
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a xenograft 
model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as we are studying 
prostate cancer, the use of male mice only is appropriate
Experimental and control groups:
SCID mice were randomly divided into four groups (n = 7/group) with no significant difference in tumor volumes
On day zero, mice were administered intraperitoneal injection of MGF-AuNP agent in DPBS (100 µL) (or saline for 
the control group) as follows:
Group 1-saline treated
Group 2-MGF-AuNPs treated (0.5 mg/kg bw)
Group 3-MGF-AuNPs treated (1.0 mg/kg bw)
Group 4-MGF-AuNPs treated (1.5 mg/kg bw)
The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a control for the evalua-
tion of complete blood count (CBC) values and body weight measurements. Animals were subjected to vaporizer 5% 
isoflurane and sacrificed at the end of study (Day 42)
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Items Recommendation Our response with section/line number or reason for not reporting
Randomization
4 (a) State whether randomization was used 
to allocate experimental units to control 
and treatment groups. If done, provide the 
method used to generate the randomiza-
tion sequence
(b) Describe the strategy used to minimize 
potential confounders such as the order of 
treatments and measurements, or animal/
cage location. If confounders were not 
controlled, state this explicitly
Mice received ear tag identifiers under inhalational anesthesia (isoflurane/oxygen) followed by unilateral, subcutane-
ous hind flank inoculations of 10 ×  106 PC-3 cells suspended in 0.1 mL of sterile Dulbecco’s phosphate buffered saline 
(DPBS) and Matrigel® (2:1, v:v). Solid tumors were allowed to develop over a period of 3 weeks, and animals were 
randomized (Day 0) into control and treatment groups (n = 7) having no significant difference in tumor volumes 
(p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes were estimated from caliper measurements 
using the formula V = length × width × depth. On Day 8, animals in the treatment group received intraperitoneal 
administrations of MGF-AuNP agent in DPBS (100 µL) while under inhalational anesthesia in doses as outlined in 
the following section. Similarly, control animals received 100 µL of saline intraperitoneally. No significant difference 
(p = 0.93) in tumor volume or body weight (p = 0.21) was noted between the groups. Tumor volumes, body weights 
and health status were then determined twice each week
All animal facilities at the Harry S. Truman Memorial Veterans Hospital and the University of Missouri, Columbia, 
Missouri, were visited daily by the veterinarian care staff, inspected by the institutional animal care and use commit-
tee members throughout the investigation
Mice were examined daily, and removed from the study if unresponsive to supportive care, moribund, if weight 
loss is > 20% body weight or if tumor size > 5  cm3 with poor body condition (hunched posture and loss of > 20% 
body weight, or easily palpated exoskeleton) or with lassitude with written protocols to euthanatize such animals to 
minimize animal discomfort
Blinding
5. Describe who was aware of the group 
allocation at the different stages of the 
experiment (during the allocation, the 
conduct of the experiment, the outcome 
assessment, and the data analysis)
All experiments of MGF-AuNPs involving animals were approved by the Institutional Animal Care and Use Com-
mittees (IACUC, protocol number 8767) of the Harry S. Truman Memorial Veterans Hospital and the University of 
Missouri were performed according to the Guide for the Care and Use of Laboratory Animals. All animal facilities at 
the Harry S. Truman Memorial Veterans Hospital and the University of Missouri, Columbia, Missouri, were visited 
daily by the veterinarian care staff, inspected by the institutional animal care and use committee members through-
out the investigation
The animal modeling staffs and veterinarians, who conducted our animal experiments, have over 20 years of experi-
ence in all aspects of pharmaceutical testing through placebo-controlled, blinded pre clinal investigations in tumor 
bearing mice. Such data has formed the basis for seeking approval for Phase 1 trials of various drugs discovered by us 
in the past. In the current investigation, as reported in our manuscript, our staff have exercised due care and caution 
to perform blinded experiments in prostate tumor bearing xenografts in SCID mice with our nanomedicine agents 
MGF-AuNP with saline in controls
Outcome meas-
ures
6 (a) Clearly define all outcome measures 
assessed (e.g. cell death, molecular markers, 
or behavioral changes)
(b) For hypothesis-testing studies, specify 
the primary outcome measure, i.e. the out-
come measure that was used to determine 
the sample size
Outcome measures:
Morbidity: As accepted by the institutional Animal Care and Use Committees (IACUC, protocol number 8767) of 
the Harry S. Truman Memorial Veterans Hospital and the University of Missouri Guide for the Care and Use of 
Laboratory Animals, we defined morbidity to include any animal where one of the following conditions exists: the 
tumor volume exceeds 5  cm3, ulceration of the overlying skin of the tumor is observed, ulceration of the tumor itself 
is observed, body weight-loss of more than 20% is noted, and/or significant illness/depression (whether or not related 
to the experimental protocol) is observed. Animals exhibiting any signs of morbidity, as defined, will be sacrificed 
immediately to minimize and alleviate any unnecessary pain and suffering. Mortality was evaluated by measuring any 
differences in the total survival times between groups as a function of study termination time
These studies required 7 mice per experimental group to provide meaningful statistical results based on the expecta-
tion of accurately detecting a 20% difference in experimental tumor groups
Hypothesis validation and expected primary outcome: The overall hypothesis was to validate the antitumor char-
acteristics of the experimental nanomedicine agent. The following groups of control and tumor bearing mice were 
administered intraperitoneal injections of MGF-AuNP agent in DPBS (100 µL) (or saline for the control group) as 
follows:
Group 1-saline treated
Group 2-MGF-AuNPs treated (0.5 mg/kg bw)
Group 3-MGF-AuNPs treated (1.0 mg/kg bw)
Group 4-MGF-AuNPs treated (1.5 mg/kg bw)
The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a control for the evalua-
tion of complete blood count (CBC) values and body weight measurements. Animals were subjected to vaporizer 5% 
isoflurane and sacrificed at the end of study (Day 42)
50–80% reduction in tumor volumes in the treated groups, as compared to the control group, with minimal/no 
adverse toxic side effects, (Groups 2–4) was the expected outcome of this hypothesis driven investigation
Throughout the study, the animals were monitored for their tumor volume (groups 1–4), body weight and overall 
health (group 1–5). Mice were examined daily, and removed from the study if unresponsive to supportive care, 
moribund, if weight loss is > 20% body weight or if tumor size > 5  cm3 with poor body condition (hunched posture 
and loss of > 20% body weight, or easily palpated exoskeleton) or with lassitude with written protocols to euthanatize 
such animals to minimize animal discomfort
At the end of the study (day 42) animals were subjected to vaporizer 5% isoflurane and before being sacrificed and 
following samples were collected from group 1–4, blood, tissues (spleen, liver, and tumor)
Blood samples from all groups were used for complete blood count (CBC) values
The tissues (spleen, liver, tumor and blood) were submitted to the University of Missouri Neutron Activation Analy-
sis (NAA) facility at the University of Missouri Research reactor (MURR) for the accurate quantification of gold in 
various tissues by NAA analysis
Statistical 
methods
7 a. Provide details of the statistical 
methods used for each analysis, including 
software used. b. Describe any methods 
used to assess whether the data met the 
assumptions of the statistical approach, 
and what was done if the assumptions were 
not met
Mortality was evaluated by measuring any differences in the total survival times between groups as a function of 
study termination time. These studies required 7 mice per experimental group to provide meaningful statistical 
results based on the expectation of accurately detecting a 20% difference in experimental tumor groups
All experimental data are described as mean ± SEM. Statistical analysis was carried out using the one-way analysis of 
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Items Recommendation Our response with section/line number or reason for not reporting
Experimental 
animals
8 (a) Provide species-appropriate details of 
the animals used, including species, strain 
and substrain, sex, age or developmental 
stage, and, if relevant, weight
(b) Provide further relevant information on 
the provenance of animals, health/immune 
status, genetic modification status, geno-
type, and any previous procedures
Species-appropriate details:
(a) Male SCID mice (4–5 weeks of age; Taconic Farms, Hudson, NY) were housed in a temperature and humidity-
controlled pathogen-free barrier facility
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a xenograft 
model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as we are studying 
prostate cancer, the use of male mice only is appropriate
Male SCID mice (4–5 weeks of age; Taconic Farms, Hudson, NY) weighing 20–25 g in weight were housed in a 
temperature and humidity-controlled pathogen-free barrier facility
(b) Description of animal procurement, housing, and grouping: Animals were maintained on a 12 h light–dark cycle 
and had access to sterilized standard chow and water ad libidum. Animals were allowed to acclimate for 7–10 days 
prior to initiation of work. Human prostate cancer cell line PC-3 was obtained from the American Type Culture 
Collection (ATCC; Manassas, VA), and cultured according to ATCC recommendations by the University of Missouri 
Cell and Immunobiology Core facility. Mice received ear tag identifiers under inhalational anesthesia (isoflurane/
oxygen) followed by unilateral, subcutaneous hind flank inoculations of 10 ×  106 PC-3 cells suspended in 0.1 mL of 
sterile Dulbecco’s phosphate buffered saline (DPBS) and Matrigel® (2:1, v:v). Solid tumors were allowed to develop 
over a period of 3 weeks, and animals were randomized (Day 0) into control and treatment groups (n = 7) having 
no significant difference in tumor volumes (p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes 
were estimated from caliper measurements using the formula V = length × width × depth. On Day 8, animals in the 
treatment group received intraperitoneal administrations of MGF-AuNP agent in DPBS (100 µL) while under inha-
lational anesthesia in doses as outlined in the following section. Similarly, control animals received 100 µL of saline 
intraperitoneally. No significant difference (p = 0.93) in tumor volume or body weight (p = 0.21) was noted between 
the groups. Tumor volumes, body weights and health status were then determined twice each week. At the end of the 
study (Day 42), mice were euthanized by cervical dislocation, and blood sample was collected by cardiac puncture. 
Samples of spleen, liver, tumor, and blood were harvested, weighed and submitted to the University of Missouri 
Neutron Activation Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the accurate 
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Items Recommendation Our response with section/line number or reason for not reporting
Experimental 
animals
9 For each experimental group, including 
controls, describe the procedures in enough 
detail to allow others to replicate them, 
including:
(a) What was done, how it was done and 
what was used
(b) When and how often
(c) Where (including detail of any acclima-
tization periods)
(d) Why (provide rationale for procedures)
Full experimental details of all nnimal studies reported in our manuscript:
Ethics Committee Approvals:
All in vivo work has been performed at an IACUC approved laboratory and in accordance with ARRIVE guidelines 
for animal welfare. Animal studies were approved by the Institutional Animal Care and Use Committees of the Harry 
S. Truman Memorial Veterans Hospital and the University of Missouri and were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals under an IACUC approved protocol number 8767
NOTE: We have over three decades of experience in conducting hypothesis driven cancer research with in vivo 
models using tumor bearing SCID mice to minimize discomfort and adverse effects in study animals (both control 
and treated animals). Here are a few representative publications where we have outlined similar in vivo investigations 
which have been accepted by the global scientific peers:
(4) Ravi Shukla, Nripen Chanda, and Kattesh V. Katti et al.: 198AuNP-EGCg for prostate cancer therapy: Proceedings 
of the National Academy of Sciences Jul 2012, 109 (31) 12426–12431; https:// doi. org/ 10. 1073/ pnas. 11211 74109
(5) Nripen Chanda, Vijaya Kattumuri, Kattesh
V. Katti, et al.: Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity: 
Proceedings of the National Academy of Sciences May 2010, 107 (19) 8760– 8765; https:// doi. org/ 10. 1073/ pnas. 10021 
43107
(6) Nripen Chanda, Para Kan, Kattesh V. Katti, et al.; Radioactive gold nanoparticles in cancer therapy: therapeutic 
efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing mice: Nanomedicine: Nanotechnology, 
Biology and Medicine, Volume 6, Issue 2, 2010, Pages 201–209, ISSN 1549-9634; https:// doi. org/ 10. 1016/j. nano. 2009. 
11. 001
Justification for the Use of Animals: There are no in vitro tests that can be used to substitute for the complex tumor 
microenvironment occurring in vivo when testing experimental candidates for their effectiveness as prostate cancer 
therapy agents. Our investigations of therapeutic effectiveness studies, of a new nanomedicine agent, MGF-AuNP, 
in vivo using human prostate tumor xenografts in SCID mice are necessary. Therefore, the SCID mice model with 
prostate tumor xenografts, as described in our manuscript, represents the most widely accepted and the best model 
for pre-clinical evaluations of novel therapeutic strategies ultimately intended for use in treating human prostate 
tumor patients
All experiments of MGF-AuNPs involving animals were approved by the Institutional Animal Care and Use Com-
mittees (IACUC, protocol number 8767) of the Harry S. Truman Memorial Veterans Hospital and the University of 
Missouri were performed according to the Guide for the Care and Use of Laboratory Animals
We have used severely compromised immunodeficient (SCID) mice bearing a flank model of human prostate cancer 
derived from a subcutaneous implant of 10 million PC-3 cells for therapeutic efficacy and pharmacokinetic studies 
(from Taconic Farms, Hudson, New York) were used for the therapeutic study. The mice used in our investigations 
weighed 24–27 g
In vivo bio-distribution study by Neutron Activation Analysis (NAA). To assess the gold content in tissue in SCID 
mice (n = 7). 1.5 mg/kg bw MGF-AuNPs were administered in these mice for seven weeks, while control mice (n = 7) 
did not receive any treatment with MGF-AuNPs. Tumor, spleen, liver and blood were harvested upon euthanization 
(vaporizer 5% isoflurane), put into chloridometer vials and dried for approximately 48 h at 100–120 °C. Dried tissue 
mass of approximately 0.5–1.0 g was placed into polyethylene vials (used for control of counting geometry). We 
estimated the amount of gold in various tissue samples as described previously
In vivo therapeutic efficacy study. Antitumor efficacy of MGF-AuNPs was evaluated by developing prostate 
tumor model (in SCID male mice). The SCID male mice were subcutaneously inoculated with 10 ×  106 PC-3 cells 
(suspended in 0.1 mL of sterile DPBS and Matrigel® (2∶1, v:v)) in the right hind flank under inhalation anesthesia 
(isoflurane/ oxygen). After inoculation, tumors were allowed to grow for 2–3 weeks, at which time the tumors were 
measured by digital caliper measurements and calculated as length × width × height. The mice were randomly divided 
into four groups (n = 7/group) with no significant difference in tumor volume, randomization was generated using 
the standard = RAND() function in Microsoft Excel, and the day of randomization was considered the day zero of 
therapy study. On day zero, mice were given intraperitoneal injections as follows: Group 1: saline treated (100 µL); 
Group 2: MGF-AuNPs
treated (0.5 mg/kg bw); Group 3: MGF-AuNPs treated (1.0 mg/kg bw) and Group 4: MGF-AuNPs treated (1.5 mg/
kg bw)—all in 100 µL Dulbecco’s PBS. Using this regimen, animals were treated twice per week until the end of the 
study (42 days). The animals were monitored for their tumor volume, body weight and health effects until they were 
sacrificed at the end of the study. The fifth group (n = 7) was kept as control group (no tumor and no treatment) and 
served as a control for complete blood count (CBC) values and body weight measurements. Animals were sacrificed 
at the end of study. Measurement of tumor volumes were carried out twice each week until the end of the study (Day 
42). Within two weeks (Day 14), tumor growth in the treated group (with MGF-AuNPs at 1.5 mg/kg bw), appeared to 
be slowing with respect to the controls. After 17 days of post administration (dose of MGF-AuNPs at 1.5 mg/kg bw), 
tumor volumes were two- fold lower (p < 0.005) for treated animals compared to controls. This significant therapeutic 
effect was maintained throughout our observational study. Tumor volumes for the control animals were fully six-
seven-fold greater with respect to those for the MGF-AuNPs-treated group (p < 0.0001; 0.37 ± 0.05 vs. 0.06 ± 0.02  cm3) 
groups—at three weeks, post administration of after MGF-AuNPs (1.5 mg/kg bw). These observations were indica-
tive of > 85% reduction in the overall tumor volume for the treated group. This profound therapeutic efficacy was 
observed throughout the 42 days long study. Tumors harvested from the treatment group consisted largely of necrotic 
tissue, indicating extensive death of tumor cells
The tissues (spleen, liver, tumor tissue and blood) were isolated from prostate tumor xenografts and were submitted 
to the University of Missouri Neutron Activation Analysis (NAA) facility at the University of Missouri Research reac-
tor (MURR) for the accurate quantification of gold in various tissues by NAA analysis
Results
10 For each experiment conducted, includ-
ing independent replications, report: (a) 
Summary/descriptive statistics for each 
experimental group, with a measure of vari-
ability where applicable (e.g. mean and SD, 
or median and range). (b) If applicable, the 
effect size with a confidence interval
Full description of Results/Summary (taken directly from our manuscript): In our evaluations, unilateral solid 
tumors were allowed to grow for three weeks, and animals were randomized (denoted Day 0) into control and treat-
ment groups (n = 7) with no significant differences in tumor volume. In vivo dosing involved administering on day 0 
three doses of MGF-AuNP (0.5 mg/kg bw, 1.0 mg/kg bw and 1.5 mg/kg bw—in 100 µL Dulbecco’s PBS) intraperito-
neally, while the control SCID mice received only 100 µL Dulbecco’s PBS/saline. Tumors were then measured twice 
each week until the end of the study (Day 42). Figure 11 shows results from the MGF-AuNPs-treated human prostate 
cancer bearing SCID mice. Within two weeks (Day 14), tumor growth in the treated animals started slowing down 
with respect to the control animals. Day 17, post administration of MGF-AuNPs (1.5 mg/kg bw), tumor volumes 
were two-fold lower (p < 0.005) for treated animals as compared to the control group. Three weeks, post administra-
tion of after MGF-AuNPs (1.5 mg/kg bw), tumor volumes for the control animals were fully six-fold greater with 
respect to those for the MGF-AuNPs-treated group (p < 0.0001; 0.37 ± 0.05 vs. 0.06 ± 0.02  cm3)—suggesting > 85% 
reduction in the overall tumor volume for the treated group. This significant therapeutic effect was maintained 
throughout the 42 days long study. Tumors harvested from the treatment group consisted largely of necrotic tissue, 
indicating extensive death of tumor cells
Table 1.  ARRIVE description.
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